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ABSTRACT 
Cells that are deficient in proteins involved in homologous recombination repair (HRR) have 
been shown to be hypersensitive to PARP inhibitors. While a cell may tolerate PARP 
inhibition or HRR defects alone, the combination is lethal. This phenomenon is termed 
synthetic lethality. The function of HRR signaling protein ATM is lost in 50% of mantle cell 
lymphomas (MCL). MCL is an aggressive and currently incurable subtype of Non-Hodgkins 
lymphoma. PARP inhibition might prove to be a valuable treatment option for ATM deficient 
MCL cases. 
 In this master thesis, we have investigated the alterations in cell growth, cell cycle 
distribution and DNA damage levels, as well as mode of cell death caused by PARP inhibitor 
treatment of ATM deficient lymphoid cells. Four lymphoid cancer cell lines (Reh, U698, JVM-
2 and Granta-519) were continuously exposed to the clinically relevant PARP inhibitor 
(olaparib/AZD-2281), and/or ATM inhibitor (KU-55933).  
Cell growth was reduced or inhibited in all cell lines exposed to both ATM inhibitor and PARP 
inhibitor. The ATM inhibitor alone had little effect on the measured parameters in general, 
but increased the doubling time for all cell lines, and extended mitosis of U698 and Granta-
519 cells. PARP inhibition caused a dose dependent-increase of DNA double strand breaks 
(DSB) during S phase. A G2 phase delay was induced by combined PARP and ATM inhibition. 
The cells repaired the DSBs associated with γH2AX foci during the prolonged G2 phase and 
entered mitosis without foci. Granta-519 and Reh cells became apoptotic from G2 or M in 
response to PARP and ATM inhibition, possibly because of high levels of DSBs. PARP and 
ATM inhibited U698 and JVM-2 cells suffered from mitotic catastrophe before necrosis. TP53 
deficient U698 cells endoreduplicated extensively, while JVM-2 (wildtype TP53) cells 
arrested after failed cytokinesis.  
ATM deficient/inhibited lymphoid cells are sensitized to PARP inhibitors in a cell line specific 
manner, possibly because of other underlying genetic aberrations. We propose that the 
synthetic lethality of PARP and ATM inhibition was caused by repeated cycles of incorrect or 
failed repair of DNA DSBs that occurred during replication. Even though the HRR deficient 
cells have repaired the DSBs (possibly by error-prone non-homologous end joining), they 
may still accumulate translocations and/or other structural chromosome-defects that lead to 
apoptosis or mitotic catastrophe. 
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SAMMENDRAG 
Celler som har defekter i  homolog rekombinasjon reparasjon-signalveien (HRR) har vist seg 
å være hypersensitive for behandling med PARP-inhibitorer. En celle kan tåle PARP 
inhibering eller HRR defekter hver for seg, men kombinasjonen er dødelig. Dette fenomenet 
kalles syntetisk letalitet. Tap av ATM funksjon (HRR signaleringsprotein) er funnet i  50% av 
alle mantelcelle-lymfomer (MCL). MCL er en aggressiv og p.d.d. uhelbredelig undergruppe av 
Non-Hodgkins-lymfom, der bruk av PARP inhibitorer kan vise seg å være en verdifull 
behandlingsmulighet for undergruppen som har ATM-forstyrrelser.  
I denne masteroppgaven har vi undersøkt endringer i cellevekst, cellesyklus og DNA-skade, 
samt celledød-mekanisme etter PARP inhibitor behandling. Fire lymfoide kreftcellelinjer 
(Reh, U698, JVM-2 og Granta-519) ble kontinuerlig behandlet med en klinisk relevant PARP-
inhibitor (olaparib/AZD-2281) og/eller ATM-inhibitor(KU-55933).  
Celleveksten ble redusert eller fullstendig hemmet i all cellelinjene etter samtidig ATM og 
PARP inhibering. Alene hadde ATM inhibitoren gjennomgående liten effekt på de fleste 
målte parametere, men økte doblingstiden i alle cellelinjene og forlenget mitosen for U698 
og Granta-519 celler. PARP inhibering medførte en doseavhengig økning av DNA 
dobbeltrådbrudd under S-fase. G2-fase ble forlenget som følge av kombinert PARP og ATM 
inhibering. Cellene reparerte γH2AX-foci assosierte dobbeltrådbrudd i den forlengede G2 
fasen og entret mitose uten slike foci. Granta-519 og Reh celler ble apoptotiske etter 
behandling med PARP og ATM inhibitorer, muligens på grunn av et høyt antall 
dobbeltrådbrudd. PARP og ATM inhiberte U698 og JVM-2 celler ble nekrotiske etter mitotisk 
katastrofe. De TP53-defekte U698 cellene endoreduplikerte, i motsetning til JVM-2 celler 
(har villtype TP53) som arresterte etter mislykket celledeling. 
ATM-defekte/inhiberte lymfoide kreftceller er sensitive for PARP inhibitorer. Effekten var 
cellelinje-spesifikk, noe som tyder på at andre genetiske ulikheter påvirket resultatet. Våre 
resultater tilsier at den syntetiske letale effekten av PARP og ATM inhibering ble forårsaket 
av gjentatte sykler med mislykket reparasjon av replikasjons-induserte DNA 
dobbeltrådbrudd. Selv om de HRR-defekte cellene har reparert  dobbeltrådbruddene (trolig 
med ikke-homolog endespleising), kan translokasjoner og/eller misdannelser i kromosom-
struktur akkumulere og lede til apoptose eller mitotisk katastrofe. 
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ABBREVIATIONS 
ADP Adenosine diphosphate 
ATM Ataxia telangiectasia mutated 
ATMi ATM inhibitor, KU-55933 
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1 INTRODUCTION 
1.1 AIM OF STUDY 
Two studies published in 2005 demonstrating the profound sensitivity to PARP 
inhibitors in treatment of BRCA-defective cells1,2 spurred a promising development. 
The term “synthetic lethality”3 has been used to describe the effect of combined loss 
of function of BRCA1/2 and PARP. Depletion of other homologous recombination 
repair (HRR) proteins, like the DNA damage signal transducer, ataxia telangiectasia 
mutated (ATM), have also proved synthetically lethal in combination with PARP 
inhibition4-9. The tolerable side effect-profile of PARP inhibitors has made them 
rapidly available and attractive for clinical use. In contrast to the speed of clinical 
implementation, the knowledge of the underlying mechanisms has advanced far less 
rapidly. Recent studies have highlighted the poorly understood complexity of the 
DNA repair processes, in which PARP are involved10-14, establishing the need for 
further functional studies.  
Patients diagnosed with mantle cell lymphoma (MCL) have the worst prognosis of 
malignant non-Hodgkins B-cell lymphoma patients (figure 1-1). MCL patients are 
presently being treated with high doses of chemotherapy, mainly rituximab (anti-
CD20) and CHOP (cyclophosphamide, hydrodoxydaunomycin, oncovin, and 
prednisone), resulting in a median survival of only 4-5 years15. The relapse rate is 
high and after remission, MCLs have commonly developed chemo-resistance. MCL 
and its leukemia equivalent chronic lymphocytic leukemia (CLL) have frequent 
deletions and/or mutations of ATM16-19. Fifty percent of MCL cases have disabling 
ATM alterations20,21. While the frequency of ATM loss in CLL is around 20%17,19, the 
prognosis of this patient subgroup is inferior to that of ATM-proficient CLL patients18. 
Loss of ATM function could therefore prove to be a tumor specific target for MCL 
treatment. 
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Figure 1-1: Cancer-specific survival of the main B-cell lymphoma subtypes in the series of the 
Oncology Institute of Southern Switzerland, 1980-2006. MCL indicates mantle cell 
lymphoma; FL, follicular lymphoma; MZL, marginal zone lymphoma; and DLCL, diffuse large 
cell lymphoma. This figure was published in Blood 2009, in an article by Michele Ghielmini 
and Emanuele Zucca 22.  
PARP-inhibitors may be used to treat patients with ATM-deficient lymphoid 
neoplasias. Preclinical studies of the use of PARP inhibitors in ATM-deficient cell lines 
and xenografts have had promising results, but these studies mainly focused on the 
end point of cell death4,6-9. As the basic mechanism of synthetic lethality is not well 
understood, we decided to examine the details of certain biological aspects of PARP 
inhibition. First, we wanted to establish in vitro assays for studying synthetic lethality 
and to use these to investigate the basic mechanisms of PARP inhibition in ATM-
deficient cells. We have focused on determining the kinetics of the following 
phenotypes of lymphoid cancer cell lines during 72h PARP inhibitor treatment: 
- Cell growth alterations 
- Cell cycle alterations  
- Induction of DNA DSBs 
- Mode of cell death 
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1.2 BACKGROUND 
1.2.1 CANCER 
The cumulative risk of developing cancer by the age of 75 is 34,5% for men and 
27,9% for women in Norway (2005-2009)23. Although more than 65% of these 
patients survive for at least 5 years after diagnosis (1970-2009)23, cancer is the 
number one cause of death in Norwegian males and the second most common cause 
of death in the female population (2011)24. Cancer is uncontrolled cell growth and 
termed malignant neoplasia (Greek for “new growth/formation”). Cancer cells are 
characteristically insensitive to anti-growth signals and self-sufficient in pro-growth 
signals. A cancer cell must be able to divide limitlessly and avoid cell death and 
senescence. For a solid tumor to grow above 1mm3, it must be able to develop blood 
vessels (angiogenesis). Further growth of the tumor requires ability to invade 
surrounding tissue and possibly metastasize to distal locations. These original six 
hallmarks of cancer25 have recently been complimented by four new hallmarks26. 
Among the newly added hallmarks are “avoiding destruction by the immune system” 
and “genetic instability and mutation”. When a de novo genetic alteration translates 
into a growth advantage for a cell during malignant transformation, the change will 
be one of the many steps of the miniature evolutionary process that is cancer 
development. 
1.2.2 GENETIC ABERRATIONS  
Most genetic aberrations are silent (non-functional), while some might be 
incompatible with cell survival, others are corrected by DNA repair mechanisms. 
However, unrepaired, carcinogenic errors may accumulate and thereby create 
malignant lesions. The most common genetic aberrations are subtle sequence 
changes like base substitutions and small deletions or insertions. However, genetic 
aberrations also include chromosomal translocations, and amplifications or deletions 
of large chromosome segments and whole chromosomes.  
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Exchange of a single nucleotide, called a point mutation, is the simplest form of 
genetic alteration and may be caused by either exogenous or endogenous agents. If 
a nucleotide in a coding DNA sequence becomes permanently substituted, this may 
lead to an amino acid-exchange in the resulting peptide, i.e. a missense mutation. 
Insertions or deletions of a few nucleotides may lead to changes in the reading 
frame of the affected gene. In most cases, these changes result in a premature stop 
codon and subsequent truncated mRNA transcripts (nonsense mutations). 
Translocations may occur within a chromosome or between two or more non-
homologous chromosomes. Some genetic material may be lost during this process, 
due to unsuccessful ligation of the translocated DNA-ends (unbalanced 
translocation). Even if the translocation is balanced, there is a possibility of creating 
fusion genes if the chromosome fusion sites involve coding regions. Alternatively, a 
gene may be transcriptionally regulated by the enhancer/promoter elements of 
another gene. An example of the latter is the t(11,14)(q13;q32) translocation, which 
is one of the hallmarks of mantle cell lymphoma (MCL)27,28. This translocation 
juxtaposes CCND1 (CyclinD1) on 11q with the IGH (immunoglobulin heavy chain) 
locus on 14q. The IGH enhancer element is placed upstream of CCND1, causing 
enhanced transcription of CCND1. The resulting enhanced level of CCND1 promotes 
cell cycle progression into S phase. Amplifications and deletions change the copy 
number of the genes in the affected region, thus disturbing the expression of gene-
dose regulated genes. 
Studies of cancer development have led to definition of two broad classes of 
implicated genes. Proto-oncogenes are often amplified, as overexpression of these 
genes leads to growth promotion. Gain of function-mutations, which lead to 
hyperactivation of the resulting protein, is another way of disturbing the normal 
function of the protein. A proto-oncogene becomes an oncogene when the function 
of the resulting protein is malignantly altered. Some highly growth-promoting virus-
genes inserted in the mammalian genome are innately oncogenes and can in some 
cases drive oncogenesis. Deletions or loss of function-mutations in genes that 
restricts growth, the tumor-suppressor genes, are in some cases not efficient unless 
all copies of a specific gene are affected (e.g. RB1). Other tumor-suppressor genes 
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are gene-dose regulated and affected by mutation/deletion of a single allele (e.g. 
TP53). DNA maintenance genes (caretaker genes) are also implied in cancer 
development, as they guard genomic integrity. Inactivation of DNA repair associated 
genes (through mutations or deletions) will lead to increased acquisition of DNA 
damage.  
1.2.3 DNA DAMAGE REPAIR 
Maintenance of genomic integrity is essential in normal proliferation, during 
development of organisms and in prevention of malignant transformation. The DNA 
molecule can be altered in many ways by perpetual attacks of both endogenous and 
exogenous agents (e.g. metabolites, free radicals, ionizing radiation). During one day, 
up to one million insults to the genetic material needs to be resolved in a single cell. 
Cells have developed a complex machinery of repair and checkpoint pathways to 
prevent genomic alterations in response to these insults. If the amount of DNA 
damage is too extensive, programmed cell death (apoptosis) may be induced. These 
pathways make up the DNA damage response (DDR)29, and they ensure the transfer 
of reliable genetic information throughout the generations.  
In addition to extensive proofreading and correction of base substitutions by DNA 
polymerase δ and ε in mammalian cells30, high fidelity DNA excision-repair systems 
evolved early in evolution to protect the genome. Base excision repair (BER) will for 
instance correct depurinated nucleotides and the most common point mutation 
(when a thymine is formed from a deamination of a 5-methyl cytosine). In 
mammalian cells APEX131, XRCC132 and DNA ligase III33 are essential BER proteins. In 
all eukaryotic cells, functional BER requires a DNA glycosylase, an AP endonuclease 
or AP DNA lyase, a DNA polymerase, and a DNA ligase. Nucleotide base excision 
repair (NER) is activated in response to chemically altered bases that leads to 
distortions of the α-helical structure of dsDNA. Approximately 25 nucleotides around 
the site of damage are excised during NER, in contrast to BER, which only excises the 
altered nucleotide. The DNA mismatch excision repair (MMR) corrects replication 
errors, such as base pair-mismatches and small insertions or deletions.  
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Single strand break repair (SSBR) is sometimes referred to as a separate entity of 
DNA repair. However, SSB structure is an intermediate during BER, and the 
machinery implicated in SSBR is the same as in BER. While BER, NER and MMR 
require intact complimentary DNA strands to guide their repair, some DNA repair 
mechanisms are able to repair the more severe DNA damage, DNA double-strand 
breaks (DSBs). 
Genomic information is protected by the robust structure of dsDNA with a sugar-
phosphate backbone of each strand. Extensive force is thereby required to create a 
DSB. Incidentally, DSBs are among the DNA damage events that occur most seldom. 
Identification and stabilization of DSBs are the first steps in the repair process. 
Phosphorylation of Serine139 of H2AX histones (γH2AX) close to the DNA breakage 
site occurs within seconds after a DSB34. Induction of γH2AX after DSBs leads to 
chromatin decondensation35 and recruitment of DDR-proteins36. Ionizing radiation, 
some chemotherapeutics, as well as replication fork collapse can cause DSBs. DSBs 
(identified by γH2AX foci) are often found in S and G2 phase of untreated normal and 
cancer-derived cells, they are, however, rare events in unperturbed G1
37 and mitotic 
cells38. Thus, it follows that DSBs are repaired before mitotic entry is allowed. The S- 
and G2-associated γH2AX foci have been shown to decrease after treatment with 
reactive oxygen species (ROS) scavengers, thus indicating that DSBs arise during DNA 
replication and is caused by ROS from cell metabolism39. 
Among the many proteins that participate in the DNA damage response, ataxia 
telangiectasia mutated (ATM) is one of the key players. The congenital human 
condition, ataxia telangiectasia (A-T), is an autosomal recessive disorder caused by 
inherited mutations in both ATM alleles. Homozygous A-T patients display many 
defects in their nervous- and immune-system, and have an increased risk of 
developing neoplasias. The MRN complex (MRE11-RAD50-NBS1) senses DSBs and 
recruits the inactive ATM homodimer40. Binding of ATM to NBS1 is essential to 
enable subsequent activation of ATM41-43. ATM is fully activated by 
autophosphorylation of serine1981, followed by dimer dissociation44. ATM is capable 
of inducing several signaling cascades, phosphorylating CHEK245, TP5346,47, Histone 
H2AX48, ATR49 and CtIP50.  
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MRN and ATM is necessary for induction of homologous recombination DSB repair 
through ATR49,51 and CtIP50. CtIP is recruited to damage sites by active ATM, where 
CtIP promotes the nuclease activity of MRE1150. ATR is recruited to DNA damage, via 
its binding partner ATRIP, by ssDNA coated with Replication protein A (RPA). ATR can 
further activate CHEK1. CHEK1 is thought to phosphorylate RAD5152 and BRCA253. 
NBS1 and ATM are required for this recruitment of ATR to RPA-coated ssDNA in S 
and G2
51. Additionally, ATM was recently found to be required for efficient HRR of 
DSBs in G2 after irradiation
54.  
Homologous recombination repair (HRR) is considered a highly accurate mechanism 
of DSB repair (figure 1-2, right panel). The accuracy is a result of utilizing the 
homologous sequence from its sister chromatid as template to guide repair, and HRR 
is therefore restricted to S and G2. MRN mediates resectioning of the DNA ends after 
a DSB. This generates a small 3’-overhang of ssDNA on each end. RPA is bound to the 
ssDNA55, inhibiting further resectioning and protecting the vulnerable ends. 
Recruitment of the recombinase RAD51 will substitute the RPA coating and further 
attract BRCA1, BRCA2, RAD52 and RAD54 (creating a nucleoprotein filament) 56. The 
nucleoprotein filament will search for a homologous sequence and invade the 
sequence (strand invasion), once coated with RAD51. The intermediate structure is 
called a displacement loop (D-loop). After DNA synthesis of the 3’-invading strand 
the D-loop is converted into a cross-shaped structure called a Holiday junction. 
Further DNA synthesis effectively restores both the displaced and the invading 
strand. Finally, resolution of the recombination structure requires processing by 
several helicases and nucleases. 
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Figure 1-2: Non-homologous end joining and homologous recombination repair. The figure is 
adapted from a review article by Tom Misteli and Evi Soutoglou (2009)57. 
In G0/G1 phase, the cell is dependent on non-homologous end joining repair (NHEJ) 
to resolve DSBs (figure 1-2 left panel). NHEJ does not require sequence homology 
and the DSB DNA ends must be perfectly compatible for accurate repair. Loss of 
nucleotides and even translocations are some of the results of inappropriate NHEJ 
repair of incompatible ends. NHEJ is also found to be processed through initial 
binding and modification through the MRN complex58-61 (not shown in figure 1-2). 
However, the ends will subsequently bind the Ku70/80 heterodimer. DNA bound 
Ku70/80 recruits DNA-PKcs (catalytic subunit), forming DNA-PK
62,63 . Activated DNA-
PK will tether the broken ends together64 and mediate recruitment of other end 
processing and repair proteins such as Artemis65.  
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Finally, a complex of DNA ligase IV, XRCC4 and XLF seals the break66,67. Competition 
of Ku70/80 and HRR for DSB ends is proposed to regulate the choice between the 
two repair mechanisms when sister chromatids are available68,69. It is still debated 
whether this is a competition or a collaboration70, as unique roles for the two 
pathways based on their repair kinetics have been reported. Kim et al. found that 
rapid and transient NHEJ factor assembly71 precedes, without inhibiting, the slower, 
yet persistent retention of HRR factors at the site of damage58.  
The diversity of DNA repair mechanisms forms a robust system that can withstand 
loss of one pathway as the remaining pathways continue to maintain genomic 
integrity. Loss of more than one pathway may on the other hand be lethal, which will 
be further discussed in section 1.2.7. 
1.2.4 THE CELL CYCLE 
DNA repair is essential for maintaining genome integrity. However, fixation of some 
types of damage may occur if the cell proceeds in the cell cycle. Eukaryotic cells have 
therefore evolved checkpoints that delay cell cycle progression until repair is 
completed. This will be discussed after a brief description of the normal cell cycle 
and its regulation. 
The mammalian cell cycle is a closely regulated process divided into four phases G1 
(gap phase 1), S (DNA synthesis), G2 (gap phase 2) and M (mitosis) shown in figure 1-
3. Mitosis is divided into prophase, prometaphase, metaphase, anaphase and 
telophase, and, finally, the phase of cell division is called cytokinesis. All 
chromosomes are condensed into sister chromatids during prophase. In 
prometaphase, the nuclear envelope breaks down to allow the microtubules that are 
emerging from the spindle poles to attach to the chromatids. The chromatids align at 
the spindle equator in metaphase, and anaphase is only initiated if all sister 
chromatids are attached to a microtubule from each pole (i.e. spindle assembly 
checkpoint). Destruction of sister chromatid cohesion marks the start of anaphase, 
and the separated chromatids are pulled to opposite spindle poles. During 
telophase, the segregated chromosomes become decondensed and two separate 
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nuclei form. Cytokinesis is the final stage, where the cell is cleaved into two daughter 
cells. The state of quiescence, often referred to as G0, is the withdrawal from active 
cell cycle. If stimulated, the cell is able to re-enter the cell cycle from resting in G0. 
Quiescence differs from the proposed irreversible and non-proliferative state of 
senescence72.  
The main players in the regulation of cell cycle progression are the cyclin dependent 
kinases (CDKs), and their activation is initiated by binding to a cyclin partner (CCN). 
The CCNs are expressed, repressed and/or degraded at different stages of the cell 
cycle, while the levels of CDKs are almost constant. Different CDK/CCN complexes 
are responsible for a multitude of coordinated cell cycle events, and their activity is 
again controlled by other kinases, phosphatases and ubiquitin-ligases.  
 
Figure 1-3: The mammalian cell cycle, with regulatory checkpoints. 
The cell will not start DNA replication if the environmental conditions, such as 
growth factors or inhibitory signals, are unfavorable. The cell decides in late G1 
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whether to start duplicating its DNA. The point of commitment to DNA replication is 
irreversible, and called the restriction point (RP). When the cell commences DNA 
replication it must complete the task, and in the absence of DNA damage, the cell 
cycle is completed without further growth factor signaling. The mechanisms of cell 
cycle progression mainly consist of binary “switches”, as the incompletion of mitosis 
or replication, for instance, would be disastrous.  
The switches are part of the evolved cell-cycle control system, known as checkpoints 
73. The proper order and completion of the major transitions of the unperturbed cell 
cycle are controlled by the following checkpoints (figure 1-3):  
1. G1/S-transition: the restriction point  
2. Re-replication: replication origins cannot be fired more than once 
3. G2/M-transition: DNA replication must be completed before mitotic entry 
4. Spindle assembly checkpoint (SAC): All centromeres must be connected to a 
kinetochore from each spindle to ensure faithful chromosome segregation 
DNA damage activates checkpoints in G1/S, S, G2/M and in metaphase. Induction of 
the checkpoints cause a halt of cell cycle progression (arrest) until the damage is 
repaired. The exception is the intra-S checkpoint (not related to the re-replication 
checkpoint described above), which causes a cell cycle delay. This intra-S checkpoint 
actively slows down replication forks and suppresses origin firing74. The G1/S DNA 
damage checkpoint guards against replication of a damaged template, and may 
employ the same downstream effectors as the RP. Mitotic entry with DNA damage is 
prevented by a G2/M checkpoint. Severe DNA damage will cause improper 
chromosome segregation, the cell is protected from this by the metaphase to 
anaphase-transition DNA damage-checkpoint, which employs effectors of SAC, e.g. 
MAD275 and AURKB76.  
The DNA damage checkpoints is initiated in the following order: Sensor proteins 
recognize DNA damage and relay the signal to transducers (mostly kinases).The 
transducers regulate the effector proteins that induce cell cycle arrest, DNA repair 
and apoptosis either indirectly (through transcription) or directly. The members of 
the phosphatidyl-inositol kinase-like kinase (PIKK) family of protein kinases ATM, ATR 
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and DNA-PKcs are central transducers in this signaling network, and they are involved 
in both overlapping and distinct pathways12,77. CHEK2 and TP53 are among the 
targets for ATM phosphorylation. While CHEK2 is a transducer itself, it can positively 
reinforce some of ATMs functions (e.g. TP53 phosphorylation78), but it has other 
separate functions as well, e.g. inhibition of Cdc25 phosphatases that activate CCN-
CDK complexes79-81. We have previously shown that TP53, CHEK1 and ATM have 
three separate roles in initiating the G2/M checkpoint after ionizing radiation in 
lymphoid cancer cell lines, and ATM and CHEK1 are essential to induce an early and 
late G2 arrest respectively
82. TP53 is essential for induction of the G1/S DNA damage 
checkpoint83,84.  
Tumor suppressor and gene regulatory protein TP53 is one of the most important 
caretakers of genome integrity85. CDKN1A (p21), an inhibitor of CDK-CCN complexes, 
are among the proteins that TP53 can transactivate. TP53 is a regulator of the 
balance between cell death and repair in response to DNA damage, by either 
stimulating transcription of pro-apoptotic genes or DNA repair-associated genes86. 
1.2.5 CELL DEATH 
The tightly controlled balance of cell division and cell death maintains tissue 
homeostasis. Several different mechanisms induce cell death. Based on differences 
in morphology, these are divided into necrosis, apoptosis, autophagy and mitotic 
catastrophe87.  
Mitotic catastrophe is not established as a separate entity of cell death. It is most 
commonly described as cell death during or after catastrophic chromosome 
segregation in mitosis. Morphological features like micronuclei or multiple nuclei87  
are markers of mitotic catastrophe (figure 1-4). It is debated whether mitotic 
catastrophe is a cause of death or a separate cell death mechanism88, as the cell 
utilizes either the apoptotic machinery (DNA damage induced caspase 2 activation)89-
91 or become necrotic92. Whether or not autophagy is a separate cell death mode is 
also questioned. Autophagy is the process of intracellular degradation of organelles 
in enlarged lysosomes or autophagosomes. If this is a process accompanying cell 
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death, a mechanism of cell death or even a damage recovery-pathway is still 
debated93. 
 
Figure 1-4: Morphological characteristics of cell death by necrosis and apoptosis, as well as a 
preceding cause of cell death induction, mitotic catastrophe. 
Necrosis is a cell death mode characterized by cell swelling, loss of membrane 
integrity and subsequent leakage of the intracellular fluid into the surroundings 
(figure 1-4). Cytotoxic enzymes (mainly released from disintegrated lysosomes) 
degrade internal cell structures. When these are released into the extracellular 
matrix, they can trigger cell death of neighboring cells as well as severe 
inflammation. In contrast to apoptosis, necrosis is considered an uncontrolled mode 
of cell death in response to massive injury or energy depletion. New findings indicate 
that this may not be the case for all necrotic events, as induction of necrosis through 
death receptor signaling is reported to be activated by FAS ligands94-96. 
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Apoptosis or programmed cell death is an active enzymatic process. Proper initiation 
of apoptosis is crucial to prevent accumulation of damaged or excessive cells. 
Apoptosis is morphologically characterized by cell shrinkage, chromatin 
condensation, membrane blebbing, DNA fragmentation and formation of apoptotic 
bodies (figure 1-4). Apoptosis is induced by both internal and external signaling and 
the two separate pathways are respectively denoted: The intrinsic and extrinsic 
apoptotic pathway. Intercellular signaling predominantly from the immune response 
activates the extrinsic pathway, while genotoxic stress primarily activates the 
intrinsic pathway. Both pathways utilize members of the caspase family of cysteine 
proteases to initiate and execute apoptosis. A balance of the relative levels of pro- 
and anti-apoptotic proteins controls induction of the intrinsic pathway. Anti-
apoptotic proteins (e.g. MCL1 and BCL2) inhibit cytochrome c release into the 
cytoplasm from channels of the outer mitochondrial membrane, while the pro-
apoptotic proteins (e.g. BAX, BAD and BAK) have the opposite function. Release of 
cytochrome c or death factor signaling (from ligands like FASL, TNFα and TRAIL) will 
lead to activation of the “executioner” caspases -3 and -7 through large complexes 
called the apoptosome and DISC (death inducing signaling complex) respectively. The 
effector caspases cleave multiple regulatory (e.g. PARP and TP53) and structural 
proteins (e.g lamins and actins). Finally, the apoptotic cell will present phosphatidyl 
serine residues on its cell surface to initiate phagocytosis by neighboring cells. 
1.2.6 PARP 
The Poly(ADP-ribose) polymerase (PARP) family of proteins and PARP like proteins is 
identified in many entities, from dsDNA viruses and bacteria to a variety of 
eukaryotes, yet not in the yeasts S. pombe and S. cervisiae97,98. PARP proteins 
require NAD+ molecules to generate a polymer of ADP-ribose (PAR) and 
concomitantly release the by-product nicotinamid. PAR is negatively charged and 
may exist as a free polymer or be a post-translational modification of other proteins. 
PAR polymers can become several kDa in size and may be linear or branched (bound 
by glycosylic ribose-ribose links)99. PARPs (17 human members, although 10 
putative100) are capable of either mono- or poly-ADP-ribosylation (PARylation). 
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Hence, a new name is suggested, the ADP-ribose transferases (ARTs) 97. The most 
extensively studied PARP is its founding member PARP1, responsible for 90% of all 
PARylation99.  
Parp1 knockout mice are viable101, display increased sensitivity to genotoxic 
stress102, and show resistance towards inflammation103-105. Although the phenotype 
of Parp1-/- mice is quite mild, depletion of the only PARP-like gene in Drosophila 
causes larval lethality106-108. Additionally, Parp1 and 2 double knockout in mice was 
shown to be embryonically lethal109, indicating that PARP activity is essential in 
mammals as well. So far, exclusively PARP1 and PARP2 have been found to be 
activated by DNA breaks and have a DNA-binding domain (zinc finger binding 
domain)110,111. Although PARP1 PARylates many targets, it mostly PARylates itself112, 
and DNA damage enhances this activity113. The autoPARylation is suggested to cause 
PARP1 to be repelled from the DNA lesions, as the PAR-polymer and DNA are both 
negatively charged114.  
Among the many targets for PARylation by PARP1 are transcription factors such as 
TP53115,116 and NF-κB117, histones99 and enzymes such as AURKB (Aurora kinase B)76. 
The dramatic increase of PAR polymer levels after induction of DNA damage is 
transient (half-life of seconds to minutes), as the polymers are rapidly catabolized by 
PAR glycohydrolase (PARG) 118,119. The removal of PAR from PARP allows new DNA 
binding120 . Although PARP1 is abundantly expressed (≈0.5 million copies per cell121 ), 
the basal level of PARG activity is much higher than that of PARP. Removal of toxic 
amounts of PAR by PARG is essential as PARG-/- mice die early in embryogenesis122 
PARG was until recently the only known PAR-degrading enzyme, when mithocondrial 
PAR was found to be degraded by ARH3123. 
Since the discovery of the caspase 3 target PARP1124, there has been extensive 
research efforts into the functions of PARPs. Although numerous and diverse 
functions of PARPs have been discovered, the underlying mechanistic explanations 
are in some cases conflicting. The established role of PARP1 as a BER/SSBR 
protein102,125,126, have been challenged by further studies demonstrating that PARP1 
depletion only slow down BER initiation14,127 or does not affect BER efficiency at 
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all128. Moreover, BER is an essential process and knockout of either Xrcc1129 or 
Apex1130 is lethal early in embryogenesis, while Parp1 knockouts are viable131. 
Inhibition of PARylation and subsequent PAR-degradation has been reported to 
retard efficient repair of SSBs14,132-134, possibly because of PARP1s role in attracting 
the scaffold protein XRCC1 to the site of damage135. PARP1 has also been shown to 
PARylate ATM in response to DNA damage6,136. PARP1 aggregation at DNA DSBs137 is 
required for rapid accumulation of MRN-complex proteins NBS1 and MRE11138. All of 
which further establishes PARP1 as a DDR involved protein. 
The massive effort put in to development of PARP inhibitors, have resulted in an 
array of small molecules with different actions. The first generation of NAD+ analogs 
(nicotinamide and 3-aminobenzamide) was not very specific. However, the 2nd  
generation of competitive inhibitors of the enzymatic site e.g. veliparib (ABT-888), 
PJ34 and olaparib139 and the 3rd generation of covalent irreversible inhibition of the 
DNA binding domain (iniparib)140 have evolved to be highly specific and potent. Most 
PARP inhibitors inhibits both PARP1 and PARP2, yet they have low adverse effects on 
normal tissue141-145. In fact, the side effects are so mild that patients can be exposed 
to PARP inhibitors over several months without additional toxicity (olaparib was 
continuously administered for 168 days in two phase II-studies146,147). Several of 
these inhibitors have undergone more or less successful clinical trials 141,142,146-150. 
The clinical trials and preceding development of PARP inhibitors were a result of two 
promising studies by Bryant et al.2 and Farmer et al.1 in 2005 demonstrating 
synthetic lethality by inhibition of PARP in BRCA1/2-defective cells. Depletion of 
other DDR proteins such as ATM, ATR and CHEK1 were identified in a siRNA screen 
searching for kinases that increased sensitivity to PARP inhibitors151. PARP inhibitors 
are promising anti-cancer agents, especially since PARP expression have been shown 
to be upregulated in several cancer types; hepatocellular carcinoma152, malignant 
lymphoma153 and early stages of colorectal carcinogenesis154, as well as known HRR-
deficient malignancies13. The latter has been shown to be HRR deficiency-
dependent, as the upregulation is reverted in response to BRCA2 reconstitution in 
vitro13.  
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1.2.7 SYNTHETIC LETHALITY: PARP INHIBITION AND HRR DEFECTS 
The term synthetic lethality describes the fatal combined loss of two genes/proteins, 
even though loss of either of the two is compatible with life. First described in 
Drosophila over 60 years ago155, synthetic lethality  have long been proposed as a 
cancer treatment strategy156, yet only one synthetic lethal treatment approach have 
reached the clinic so far.   
Although the initial in vitro studies1,2 seemed very promising, phase II studies of 
PARP inhibitor (olaparib) treatment of BRCA1/2-defective breast and ovarian cancer 
have not had the expected effect, with 41146 and 33%147 objective response rate 
(ORR), respectively. A phase II study of metastatic TNBC (without regard to BRCA-
status) increased the overall response rate from 32% to 52% by addition of iniparib 
to gemcitabine and carboplatin (GC) treatment (without increasing normal tissue-
toxity of GC)148. However, the following phase III studies using PARP inhibitor iniparib 
in combination with GC as first line-treatment of triple negative breast cancer (TNBC) 
and non-small cell lung carcinoma, have been reported (both at ASCO 2011, and 
from the manufacturer Sanofi) to fail their primary goal of increased overall survival. 
The lack of patient selection by BRCA-status makes it harder to demonstrate 
synthetic lethality in clinical studies. Additionally, the PARP inhibitory effect of 
iniparib has recently been disproven157,158. Elevated PARP expression has been 
suggested as a biomarker for response to PARP inhibitor treatment, as this is shown 
in vitro to be correlated to PARP inhibitor response13. On a whole, it has now 
become clear that the failure to demonstrate an equal response in clinical trials as in 
in vitro/vivo studies is due to a poor understanding of the consequences of PARP 
inhibition on the molecular level. Future studies on the underlying mechanisms 
behind the synthetic lethality of PARP inhibition and defective homologous 
recombination repair (HRR) are therefore warranted. 
When synthetic lethality of PARP inhibition in HRR-deficient cells first was 
discovered1,2, the role of PARP in BER/SSBR was the proposed explanation. Cell death 
was until recently thought to be caused by accumulation of unrepaired DNA SSBs 
due to PARP inhibition. These were converted into DSBs during replication, and the 
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subsequent failure to repair these by HRR would be incompatible with life (figure 1-5 
A). This was the leading functional model until considerable amounts of 
experimental results accumulated to contradict or complicate this explanation10-14. 
Most importantly, the amount of SSBs was not increased after PARP inhibition, 
shown both by the alkaline DNA unwinding assay14 and the alkaline comet assay13. 
Moreover, XRCC1 depletion of HRR-defective cells did not cause synthetic lethality12, 
and combining XRCC1 depletion with PARP inhibitors actually created an unexpected 
synthetic lethal effect10,14. These data clearly demonstrated that the role of PARP1 in 
attracting XRCC1 to SSB repair135 could not be responsible for the phenotype induced 
by PARP inhibition.  
Professor Thomas Helleday has lately proposed two new models of PARP inhibition 
in HRR-deficient cells, rejecting the formerly accepted hypothesis159. The first is 
termed “PARP trapping model” (figure 1-5 B) and is based on a suggested difference 
in sensitivity to PARP inhibitors and PARP depletion (RNAi techniques). Indicating 
that catalytically inactive PARP is not inhibited from DNA binding, but the lack of 
subsequent auto-PARylation prevents PARP from being repelled from DNA. Some 
results support this theory2, while others have not found a profound difference 
between depletion and inhibition1,12. A possible explanation for this discrepancy may 
be that the effect of RNAi-mediated knockdown does not last for many cycles, and 
PARP inhibitor induced kill of HRR-deficient cells is normally analyzed after 7-12 
days. The model further postulates that inhibited PARP is trapped onto DNA lesions, 
thereby becoming an obstacle for passing replication forks, much like the action of 
topoisomerase I inhibitors160. The subsequent replication fork collapse will produce a 
one-sided DSB (the Okazaki fragment in process). These DSBs will not be repaired or 
be incorrectly repaired by NHEJ in the absence of functional HRR.  
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Figure 1-5: Models of PARP inhibition in HRR defect background. Presentations of the 
original model (A), PARP-trapping model (B) and Replication restart model (C) are from 
Thomas Helleday’s article:  “The underlying mechanism for the PARP and BRCA synthetic 
lethality: Clearing up the misunderstandings” (2011)159 . PAR-polymers are depicted around 
PARP1-protein in A and C. “The balance of DSB repair mechanisms” model (D) is adapted 
from a figure in a review article by Amal Aly and Shridar Ganesan (2011)161. 
The second model called “Replication restart model” (figure 1-5 C) is based on the 
involvement of BRCA2162 and RAD51163 in replication fork stabilization/restart, and 
the reported affiliation of PARP1 at replication forks11,164. The model suggests that 
lethality is caused by abolishing both BRCA-mediated and PARP-dependent 
replication restart. However, PARylation was not found to colocalize with γH2AX and 
RPA foci in BRCA2-deficient cells, indicating that the PARP overexpression in these 
cells is not affiliated with stalled replication forks13. Recently, PARP1 and BRCA2 was 
found to prevent Mre11 dependent degradation of stalled replication forks, and 
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acquired resistance towards PARP inhibition was correlated with reduced Mre11 
foci165. 
Several studies have demonstrated an unexpected rescue of the PARP inhibitor 
induced synthetic lethality in HRR defective cells after additionally inhibiting 
NHEJ9,12,166,167. PARP1 may compete with Ku70/80 for DNA ends131,167-169, or 
Ku70/80-affinity to DSBs could be decreased by PARylation of Ku70/80170. This 
suggests a third model of PARP inhibition in HRR-defective cells; tilting the balance of 
DSB repair mechanisms, towards the error-prone NHEJ (figure 1-5 D). Disturbing 
NHEJ-proteins in vitro by DNA-PKcs inhibition or depletion (by RNAi) of DNA-PKcs, 
Ku80, Artemis or DNA ligase IV all alleviate the synthetic lethal phenotype induced 
by PARP inhibition in HRR-defective cells 9,12,167. Additionally, the severe 
immunodeficiency of DNA-PKcs
-/- mice was abolished after additional Parp1-/- 
knockout166. Other unexpected results of PARP inhibition are the rescue of PARP 
inhibitor-sensitivity in BRCA1-defective cells by loss of 53BP1171. 53BP1 is a TP53 
activating and DSB-binding protein172, and is found to guide DSB repair towards NHEJ 
in the absence of BRCA1171.  Severe structural chromosome aberrations have also 
been reported in BRCA1/2-defective cell lines after PARP inhibition1, indicating high 
activity of low fidelity repair. Radial chromosomes have been reported in BRCA1 
mutants rescued by TP53 or 53BP1 knockout171. A recent study of the requirement 
of 53BP1 and γH2AX in Parp1-/- mice, reported that additional H2AX knockout 
induced synthetic lethality and proposed NHEJ associated repair to be 53BP1-
dependent173. The DSB repair balance model still does not give an explanation as to 
how repair is facilitated in the combined absence of HRR, NHEJ and PARP (figure 1-5 
D, lower right quadrant), although a reconstitution NHEJ and HRR have been 
proposed161. 
Efforts have also been put into researching synthetic lethality induced by depletion 
of other HRR proteins combined with PARP inhibition4-9,13. Several studies have 
established that loss of function of ATM is synthetically lethal when combined with 
PARP inhibitor treatment4,6-9. Although, Atm and Parp1 double knockouts were 
found to die at gastrulation5. The in vitro and in vivo studies revealed that synthetic 
lethality of ATM and PARP loss is somewhat less potent than that of PARP and 
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BRCA1/24,6-9. However, most of these studies have solely focused on the potency of 
PARP inhibitors on cell death-induction. The study by Aguilar-Quesada et al. reported 
that ATM is activated by PARP inhibitor-induced DNA DSBs6. Moreover, Williamson 
et al. found that DNA-PK inhibition rescued synthetic lethality of PARP inhibition in 
ATM-deficient cells, and that additional synthetic lethality by PARP inhibition was 
observed in ATM- and TP53-defective cells9. Thus, inhibition of PARP in an ATM- 
deficient setting requires further study to elucidate its full potential and mechanism. 
2 MATERIALS AND METHODS 
Supplier information (including product numbers) regarding all materials used in this 
study is listed in the appendix. Detailed recipes for the different solutions needed to 
perform the methods described in this chapter, can also be found in the appendix. 
The specifications and dilutions of antibodies used are listed in a separate section in 
the appendix. Supplier and product information of instruments and software are 
listed continuously in the text. 
2.1 CELL CULTURE AND TREATMENT 
2.1.1 CELL LINES 
Reh is derived from a pre-B cell acute lymphoid leukemia (ALL) patient174. U698 is 
derived from a diffuse large cell lymphoma175. JVM-2 is an Epstein-Bar virus (EBV)-
transformed B-lymphocytic leukemia (B-CLL) cell line176 which was acquired from the 
Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, 
Germany). There are several studies indicating that B-CLL s carrying the t(11,14) 
translocation may correspond to blastoid MCL variants177, and use of the JVM-2 cell 
line as a model system for MCL is well established. Granta-519 is an EBV-
transformed cell line from a high-grade MCL relapse patient with t(11,14) 
translocation. Granta-519 was also purchased from DSMZ178. Granta-519 is ATM-
deficient with one ATM allele deleted179, and the other allele containing a missense 
mutation R2832C in the ATM kinase domain180. All cell lines were confirmed free of 
mycoplasma infection before use. 
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2.1.2 CULTURE CONDITIONS 
All cell lines were incubated at 37 °C with 5 % CO2 and H2O-saturated air in a Nu-
5510/E/G incubator (NuAire, Plymouth, MN). Reh, U698 and JVM-2 cells were grown 
in RPMI 1640 containing 10%(v/v) fetal bovine serum and 1%(v/v) penicillin-
streptomycin and 2mM L-glutamine. Granta-519 cells were first grown in Dulbecco’s 
Modified Eagle Medium (DMEM) as recommended by DSMZ with the same 
supplements.  
Comparison of growth rates of Granta-519 in DMEM and RPMI 1640 over 4 weeks 
indicated that there was a growth advantage in the RPMI 1640-medium and this 
medium was later used for all experiments involving Granta-519 cells. Cells were 
split and reseeded every Monday, Wednesday and Friday at a density of 3.0·105 
cells/ml for U698 and Reh and 1.5·105 cells/ml for JVM-2 and Granta-519. Cells were 
grown and handled in a sterile environment, to prevent infections from bacteria and 
fungi.  
2.1.3 CELL TREATMENT 
All cells treated with the PARP inhibitor olaparib/AZD2281 139 were seeded in their 
normal culture medium containing 0.3 – 10μM PARP inhibitor (PARPi) for the 
duration of the experiment. Stock solutions of both 1 and 10mM olaparib in DMSO 
were prepared from dry state. Initial experiments with 1.0, 3.0 or 10μM PARPi alone 
in ATM proficient cells treatment for 48h revealed equally severe cell cycle arrests 
induced by both 3 and 10µM, therefore 3μM was selected as the highest 
concentration to be used in further experiments. Patients that received 200mg or 
400mg of olaparib twice each day were reported to have blood plasma 
concentrations of olaparib ranging from 1.38 to 20.0µM145. All cells treated with the 
ATM inhibitor KU-55933181 were seeded in their normal culture medium containing 
10μM ATM inhibitor (ATMi) for the duration of the experiment. The stock of ATMi 
was prepared from dry state into a 10mM solution in DMSO. 
Reh, U698, Granta-519 and JVM-2 cells were all treated for 72h with three different 
concentrations of the PARPi alone or in the presence of 10μM ATMi. Untreated 
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control (receiving vehicle alone) and ATMi alone control were also included for each 
cell line in every experiment. Chosen experimental and clinically relevant 
concentrations of PARPi were 0.3μM, 1μM and 3μM. The experimental layout is 
illustrated in figure 2-1. The cultures not treated with ATMi were all given equivalent 
amounts of DMSO, the final DMSO concentration in the cultures ranged from 0.10-
0.13%. In order to keep the cells growing at an exponential rate for the duration of 
the experiment, an appropriate starting density of each cell line was chosen. The 
experiments started at following cell densities: Reh at 250.000cells/ml, U698 cells at 
200.000cells/ml, JVM-2 at 100.000cells /ml and Granta-519 at 120.000cells/ml. Reh 
and U698 cells were treated in 25cm2 culture flasks, with a starting volume of 10ml. 
JVM-2 and Granta-519 were treated in 75 cm2 culture flasks and, with a starting 
volume of 20ml.  
Cells were harvested from each culture at 24, 48 and 72h after treatment. 2ml (Reh 
and U698) or 4ml (JVM-2 and Granta-519) of the culture was washed once in 
phosphate buffered saline (PBS) and then fixed in 1ml -20°C, 100% methanol, and 
kept at -20°C until staining. 0.5ml (Reh and U698) or 1ml (JVM-2 and Granta-519) of 
the harvested cells was immediately counted on a Coulter Counter. 0.5ml (Reh and 
U698) or 1ml (JVM-2 and Granta-519) of each culture was also harvested for 
immediate live cell staining. 
 
Figure 2-1: Experimental layout of 72h PARP inhibition in each cell line with or without ATM 
inhibition. 
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The flux of cells into mitosis for all the cell lines was monitored by adding 1μg/ml of 
the microtubule-polymerization inhibitor nocodazole182 for 6h prior to cell harvest. 
In cells with proficient spindle assembly checkpoint, nocodazole treatment causes 
MAD2 binding of all kinetochores, resulting in a cell cycle arrest in metaphase183,184. 
The cells were first treated with vehicle alone (DMSO), 3μM PARP inhibitor and/or 
10μM ATMi, and harvested at 24h and 72h. A control of each sample (not treated 
with nocodazole) was also harvested at the same time. Cells were fixed at the time 
of harvest as described above.  
A 144h continuous exposure of U698 cells with vehicle alone or 3μM PARP inhibitor 
with/without ATMi was replicated twice. Nutrient depletion of the medium was 
avoided by medium substitution after 72h treatment. The cells were spun at 500g for 
4 minutes, before 85% of the old medium was substituted with fresh medium 
containing the same concentrations of PARPi and/or ATMi. Cell growth measured by 
Coulter Counter and fixed samples after 72h for these experiments were similar to 
the previous three replicates of 72h treatment. 
Cells with or without 10μM ATMi was irradiated with 4Gy for protein expression 
analysis. X-irradiation was executed at a dose rate of 1Gy/min in a CP160 X-ray 
generator (Faxitron, Tucson, AZ) at 160kV and 6.3mA. One hour after irradiation, the 
cells were washed once in ice cold PBS. 
2.2 CELL STAINING 
The appendix contains detailed recipes, as well as specifications and suppliers of all 
primary and secondary antibodies used in this section.  
2.2.1 FIXED CELL STAINING 
An automated cell staining procedure for fixed cell samples was developed using the 
microplate washer ELx405 Select (BioTek, Winooski, VT) and the microplate sample 
processor Precision XS (BioTek). The spatial properties of all vessels and tips had to 
be defined for the microplate processor by a procedure called “stepping”. This 
procedure determines the travel margins for the microplate processor, in x-, y-, and 
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z-direction, for instance making sure the tips reaches the desired depth in a defined 
sample volume and preventing crashes of the mobile parts. BD Falcon 5 ml 
polystyrene tubes can be used directly on all the flow cytometers available in the lab. 
These tubes have good pellet visibility and electrostatic properties. The supplied 48 
tubes-rack allowed these tubes an unacceptable margin of motion within each tube 
position, which could potentially be damaging for the precise movement of the 
instrument. A new 48 tubes-rack specifically fitted for the smaller diameter of the 
5ml BD Falcon tubes was therefore made at our instrument workshop. 
Version 2.0 of the software Precision Power (BioTek) was used to create a sample 
processing and cell-staining program for the Precision XS microplate sample 
processor. The program contained the following steps: 
1. Transferring samples from 5ml tubes to 96 well microplates  
2. Performing a TUNEL-assay with biotinylated dUTPs 
3. Primary antibody staining of phosphorylated proteins, Histone H3 and Histone 
H2AX.  
4. Addition of fluorescently labeled secondary antibodies and fluorescence-
labeled streptavidin. 
5. DNA-staining with Hoechst 33258 
6. Returning the stained samples from the microplate to 5 ml tubes  
The fixed cell samples were manually washed in 3ml PBS. Afterwards, the samples 
were transferred with the microplate sample processors single channel pipette from 
5ml BD Falcon tubes onto a Nunclon 96 round well plate. The microplate washer was 
used for washing and supernatant aspiration between the steps in the Precision XS 
program. The ELx405 Select is equipped with the Dual Action manifold that consists 
of independent 8x12 dispenser and 8x12 aspiration tubes. Each sample wash was 
performed by a protocol administrating 200μl PBS through the dispensing manifold 
simultaneously on the walls of all wells. A suitable aspiration protocol for aspirating 
supernatant after centrifugation was designed to minimize residual fluid in each well 
while keeping cell loss at a low level. The final aspiration protocol left 15μl of fluid 
when used on a plate filled with water.  
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It is necessary that the cell pellets are sufficiently firm, as to allow aspiration. On the 
other hand, they must also be loose enough for dissolving into single cell 
suspensions upon plate vortexing or mixing by the microplate processor. Thus, 
centrifugation speed and time used was optimized for fixed suspension cells. The 
microplates were all centrifuged at 700g for 5 minutes in a GS-15R centrifuge 
(Beckman Coulter). The program for the microplate sample processor was defined to 
pre-mix and dispense all staining solutions and mix (by pipetting) the staining 
solution and cell pellet.  
The Terminal deoxynucleotidyl transferase (TdT) dUTP nick end labelling (TUNEL) 
assay was used to detect cells with fragmented DNA, which is associated with 
apoptosis. TdT can be used to catalyze the polymerization of dUTPs (biotin-labelled) 
to the free ends of DNA strand breaks. Although TdT has the ability to label blunt 
ended DSBs and 5’-overhang ends, it has strongest affinity for 3’ends. TUNEL assays 
were performed using the microplate sample processor in a volume of 20μl per well. 
The TUNEL-assay reaction solution from the Recombinant Terminal Transferase kit 
had previously been optimized for minimal reagent use (appendix), and using 
microplates instead of tubes further reduced the total volume used for each sample 
by 43%. 0.1mM DTT (a reducing agent) was added to the reaction solution (0.2M 
potassium cacodylate, 25mMTris-HCl, 25mg/ml BSA, 1.6U/µl TdT enzyme, 1.5mM 
CoCl2, 10µM biotin-16-dUTP). DTT relaxes the chromatin and frees more DNA-strand 
breaks185, increasing the sensitivity of the assay. The samples were incubated for 30 
minutes at 37°C. To stop the reaction, the samples were washed using the 
microplate washer.  
The phosphorylation of Histone H3 at serine 10 (pHistone H3) is involved in 
chromatin condensation in the G2 to prophase transition, and it is widely used as a 
marker of the onset of mitosis186-188. Anti-pHistone H3 (Ser10), diluted 1:500, was 
administered by the microplate sample processor to the sample wells in a blocking 
buffer of 5%(w/v) non-fat dry milk in PBS and incubated for 30 minutes on a 
microplate shaker in room temperature.  
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Staining of phosphorylated serine 139 on Histone H2AX (γH2AX) was used to detect 
DNA double strand breaks. The antibody was administered in a dilution of 1:500 in a 
blocking buffer of 5%(w/v) non-fat dry milk in PBS together with the anti-pHistone 
H3 antibody. 
Nuclear envelope breakdown is essential for the onset of mitosis, and reassembly 
happens during anaphase and telophase. The nuclear envelope consists mainly of 
the intermediate filaments lamins, where laminB is a major component189. To 
inspect possible multinucleation or deformed nuclei, an antibody against the nuclear 
envelope protein, LMNB2 (Lamin B2), was deployed to stain JVM-2 and U698 cells. 
The antibody was diluted 1:200 in PBS containing 5% dry milk, and incubated for 30 
minutes at room temperature.  
All samples were washed twice in PBS after primary antibody incubation. Secondary 
antibodies against pHistone H3 (PE-conjugated) and γH2AX or LaminB2 (both FITC-
conjugated) were diluted 1:50 in PBS supplemented with 5% dry milk. The staining 
for apoptosis (Cy5-conjugated streptavidin) was also added to this solution of 
secondary antibodies, in a 1:400 dilution. Incubation for 30 minutes was performed 
at room temperature, before the samples were washed once in PBS. 
Hoechst 33258 is a non-permeable nucleic acid binding fluorescent dye, with high 
affinity to adenine and thymine rich areas, efficiently excluding RNA binding. When 
the molecule binds non-covalently to areas of double stranded-DNA, the 
fluorescence is 60-fold enhanced, which is important as DNA-bound and -unbound 
Hoechst stain is at equilibrium in cells which are suspended in a Hoechst solution. As 
a final step in the staining procedure, 1.5μg/ml Hoechst 33258 in PBS was added for 
DNA staining, and incubated for at least 20 minutes.  
2.2.2 LIVE CELL STAINING 
The BD Cell Viability Kit was used to quantify the amount of dead cells in the cultures 
treated with molecular inhibitors. It contains two nucleic acid dyes with different 
membrane permeable properties, which were used simultaneously to distinguish 
cells with permeable membranes. Thiazole Orange (TO) and Propidium Iodide (PI) 
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was added directly to culture samples. TO is a permeant dye that stains the nucleic 
acids (preferably RNA) of the whole cell population, effectively excluding debris from 
the analysis. PI, on the other hand, stains only nucleic acids of cells with 
compromised membranes, i.e. dead cells. 84nM TO was added 5 minutes prior to 
flow cytometry analysis, and 4.3μM PI was added to each sample at the time of 
analysis.  
Hoechst 33528 (non-permeable) was added to a final concentration of 1.5 μg/ml to 
stain dead cells immediately prior to cell sorting of live and dead cells. 
2.3 FLOW CYTOMETRY 
Data acquired during flow cytometry measurements was processed using the FACS 
Diva Software (BD Biosciences), version 4.1.3 or newer. Cell sorting into 5ml tubes or 
directly on microscopy slides was performed in a FACS Vantage SE (BD Biosciences, 
San Jose, CA) equipped with a 50mW 351 and 355nm krypton laser, a 200mW 
488nm argon laser (both Coherent, Santa Clara, CA) and a 20mW 633nm laser 
(Spectra Physics, Santa Clara, CA). The flow cytometry analysis was performed on 
either of two BD LSRIIs equipped with the following laser combinations:  
- 60mW 355nm (JDSU, Milpitas, CA), 20mW 407nm, 50mW 488nm and 20mW 
633nm (all Coherent)  
- 100mW 405nm, 50mW 488nm, 40mW 561nm and 40mW 639nm (all 
Coherent) 
Flow cytometry is fluorescence and light scatter analysis and counting of single 
microscopic particles in suspension. A hydrodynamically focused stream of particle 
suspension is passed through one or more lasers, one particle at the time. The 
particles will be excited and scatter light when passing through each laser focus. 
Fluorescence emission and scattered light from each particle is collected by 
detectors, e.g. photomultiplier tubes (PMT), and converted into electric pulses 
(signal intensity over time) (figure 2-2 A-D). A threshold value for pulse signals in one 
of the detectors (either scatter or fluorescence) (figure 2-2 A) is set to exclude noise 
(electronic and optical) and analyze solely on particles of interest. The intensity of 
 M
at
er
ia
ls
 a
n
d
 m
et
h
o
d
s 
31 
 
the detected signal must generate a pulse height above the threshold value to be 
analyzed and counted. The detected emission intensity signal is directly proportional 
to the expression of each stained target molecule. 
Emission originating from each excitation source (laser) is directed into several 
emission detectors, enabling the simultaneous use of multiple fluorescent markers in 
the same sample. Emission is partitioned by wavelength through dichroic mirrors 
and optical filtration. Moreover, overlap of multiple emission spectra as well as 
excitation spectra may require additional fluorescence spillover-compensation of 
detected signal. The forward light scatter (1-10˚ angle from the laser) is nearly 
proportional to the size of the particle, while side scatter (around 90˚ angle) is mainly 
caused by internal structures in the cell or particle. The power of flow cytometry is 
the ability to separately analyze multiple parameters of each cell rapidly and 
combine the information from the single cell level into a detailed picture of the 
whole population.  
One signal originating from two cells (doublet) (figure 2-2 D) is a major confounding 
factor. The problem may be reduced by filtering the cell suspension, but post-
processing the data by gating strategies is still essential (figure 2-2). Gating of single 
cells requires combining the pulse width and the pulse area of one parameter. The 
parameter must be universal for the population of interest.  
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Figure 2-2: Doublet discrimination: A. One cell gives rise to an electrical pulse. Parameters 
measured of each pulse are height, width and area. B. Two differently sized cells generously 
separated in time, giving rise to proportionately sized pulses. The width of the pulse from 
the bigger cell is not increased in the same magnitude as the pulse height and area. C. Two 
cells closely separated in time. The signal reaches below the threshold value between the 
two pulses, the cells are separately analyzed. D. Two cells are attached or in immediate 
proximity and the generated single pulse is bimodal. Both pulse area and width are less than 
the sum of the pulses generated by each of the two cells, separately. A, B and C will be gated 
as single cells in a Hoechst width against area dot plot, shown on the right, while the cells 
analyzed as doublets will be gated out. 
A forward scatter (FSC) signal threshold was applied to all unfixed cell samples at a 
constant FSC detector voltage for each cell line. A Hoechst 33258 fluorescence 
threshold, of 5.000 (arbitrary units) was used for fixed cells and PMT voltage was 
individually set for each sample so the peak for G1 phase cells was placed at 50.000 
(arbitrary units). Unless it is stated otherwise, 30.000 events (signals above 
threshold) were recorded for each cell sample. 
Single cell gating, for all flow cytometry analysis in this thesis, was either done on 
Hoechst staining or on side scatter, using the area and width of each signal as 
illustrated in figure 2-2. The discrimination of doublets was done prior to all other 
analysis.  
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2.3.1 DETERMINATION OF CULTURE VIABILITY 
The BD Viability kit was employed to determine the amount of live cells in each cell 
culture sample. Each sample was directly stained with Thiazole Orange (TO) and 
Propidium Iodide (PI) before flow cytometry analysis, as described in chapter 2.2.2. 
The absolute concentration of cells was determined by adding a fixed volume of 
fluorescent microspheres (BD Liquid Counting Beads), further described in chapter 
2.5.2. TO fluorescence (510-540nm) was measured with excitation at 488nm. PI 
fluorescence (663-677nm) was measured with excitation at 561nm. There was no 
spectral overlap under these conditions. Beads and debris were excluded (figure 2-3 
A) before gating live cells from dead and injured as shown in figure 2-3 B and C. A 
stopping gate of 5000 beads was employed and the total number of recorded cells 
varied from 10.000-100.000 cells. 
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Figure 2-3: Flow cytometry analysis of live and dead Reh cells stained with propidium iodide 
and thiazole orange, after gating away debris and beads based on forward and side scatter 
(A). The untreated control (B) and cells treated with 10μM ATM inhibitor and 3μM PARP 
inhibitor (C) after 72h incubation. 
2.3.2 DETERMINATION OF CELL CYCLE FRACTIONS AFTER DNA STAINING  
DNA content of each cell was indirectly measured by the signal intensity of Hoechst 
33258 emission. As each cell’s DNA content is measured, the total distribution of the 
varying DNA content in the cells analyzed yields a cell cycle distribution for each 
sample. Hoechst 33258 fluorescence (425-475nm) was measured with excitation at 
either 405nm or 355nm for analysis (LSRIIs), and with 351/355nm for cell sorting 
(FACS Vantage SE). Analysis of the cell cycle distributions obtained by flow cytometry 
was all analyzed by version 7.2.4 of the FlowJo software (TreeStar, Ashland, OR).  
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Doublet and fragment discrimination of each sample as well as removal of apoptotic 
cells (further described in section 2.3.3) was done prior to this cell cycle analysis. The 
FlowJo software computed an automatically fit cell cycle model. Cell cycle fractions 
for 282 of 288 samples were computed by the Watson Pragmatic model190 whiles 
the 6 samples which were Watson-incompatible (no easily definable G1 peak) was 
calculated by the Dean-Jett-Fox model191. Both models fit G1 and G2/M distributions 
with Gaussian curves. However, the Dean-Jett-Fox model fits the S phase-
distribution with a 2nd degree polynomial curve, while the Watson model fits the 
acquired shape exactly and without theoretical assumptions. A total Root Mean 
Squared (RMS) value of the fit of the model is calculated from the RMS of each cell 
cycle phase model fit. In the cases where the automatic model clearly fitted the 
actual distribution incorrectly, e.g. giving negative values for the sub G1-fraction, the 
model was manually adjusted. The adjustments were guided by reduction of the 
RMS value, thereby minimizing the difference between the model and the actual 
distribution. The mean RMS value for the 288 samples was 2.4, with a standard 
deviation of 0.7. 
2.3.3 ANALYSIS OF pHISTONE H3, γH2AX AND TUNEL-ASSAY 
Hoechst 33258 fluorescence (425-475nm, DNA content) was measured with 
excitation at either 405nm or 355nm. Cy5 fluorescence (664-677nm, DNA 
fragmentation/apoptosis) was measured with excitation at either 633nm or 639nm. 
Thirty thousand events were recorded for each cell sample. Following doublet 
discrimination employing area and pulse width of the DNA signal, the fraction of 
apoptotic cells were estimated, and gated out for the further analysis of non-
apoptotic cells, in a plot of DNA content versus apoptosis. The lower boundary of the 
region defining the apoptotic cells (Cy5 positive) was set at 50% of the intensity of G1 
cells along the Hoechst 33258 fluorescence axis and just above the viable cells along 
the Cy5 axis (figure 2-4 A). This was done to avoid that fragmented apoptotic bodies 
originating from one cell were counted more than once, but may result in an 
underestimation of the apoptotic fraction when extensive fragmentation has 
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occurred. No upper border in DNA content or Cy5 intensity was employed for this 
gate. 
PE fluorescence (570-600 nm, mitosis) was measured with excitation at either 
561nm or 488nm. FITC fluorescence (525-575nm, γH2AX) was measured with 
excitation at 488nm. Only when the LSRII without a 561nm laser line was used, there 
was a need for spectral overlap compensation. In the case of 488nm excitation for 
both FITC and PE, the FITC emission will spill over into the PE fluorescence detector, 
and to a small degree from PE into the FITC detector. This was compensated for by 
subtracting about 20% of the FITC signal in the PE channel, and about 2% of the PE 
signal in the FITC channel.  
The fraction of mitotic cells was determined by setting a region around the pHistone 
H3 positive population with 4n DNA content (figure 2-4 B). Single, non-apoptotic 
cells were divided into pHistone H3 positive and negative cells. The pHistone H3 
negative cells were further subdivided in a cell cycle histogram (figure 2-4 C) and the 
γH2AX intensities of those subgroups and the mitotic cells were then determined 
(figure 2-4 D). Median γH2AX intensity for each subgroup was determined in the 
cases where the peak was a symmetrical.  This was the case for G1, S and mitotic 
cells. The distribution of γH2AX in the G2 fraction was, however, often bimodal, but 
with insufficient separation of the two populations for separate analysis (figure 3-9 
and figure S4 in the appendix). Thus, the γH2AX intensities of G2 cells were not 
calculated. 
Cell numbers in each sample varied from 250.000 to 5∙106 cells. Both specific and 
background antibody binding increased at low cell numbers. Hoechst fluorescence 
also increased at low cell numbers, but this was adjusted for by varying the PMT 
voltage, such that the G1 peak was positioned with an intensity of about 50.000 
(arbitrary units). In the cases where no G1 peak was suspected to be present, the 
sample was mixed with control cells to annotate ploidies accurately (see appendix).  
The TUNEL- and pHistone H3 positive populations were clearly separated from the 
negative population, i.e. discrete binary variables (either positive or negative). The 
position of the regions used for enumeration and gating was therefore adjusted for 
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each sample by eye to compensate for the variation in specific and non-specific 
binding. The estimation of a continuous variable; γH2AX content, however, required 
a more objective treatment of the flow cytometry data. Each cell may contain any 
given number of γH2AX foci, and the strength of the foci varies, yielding a 
distribution of γH2AX content. As shown in section 3.3 (figure 3-9 A and B), 
background due to the secondary antibody increased with decreasing cell number. 
We also noted that the γH2AX staining of G1 cells increased at lower cell numbers, 
although only a few of these cells contained γH2AX foci by microscopy, even in 
heavily treated samples (figure 3-10). Hence, the staining in G1 cells was due to non-
specific binding of the primary, as well as the secondary antibody. Assuming that 
background binding increases with DNA content and cell size, the γH2AX intensity in 
the different cell cycle phases was divided by the γH2AX intensity of G1 cells 
multiplied with the amount of DNA in that cell cycle phase. This procedure ensured 
that fold changes from G1 should be close to one if expression increases in parallel 
with DNA content throughout the cell cycle. Mid-S phase γH2AX-intensity was 
divided by 1.5 times the γH2AX intensity of G1 cells in the same sample, while 
intensity in mitosis were divided by 2 times the γH2AX intensity of G1 cells. Others 
have previously employed a similar normalization of γH2AX intensity, compensating 
for the variation in background and normal cell cycle specific differences37.  
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Figure 2-4: Gating strategy used for determining apoptotic and mitotic fraction and γH2AX 
staining intensity according to cell cycle phase of fixed cells. Reh cells treated with 3µM 
PARP inhibitor and 10µM ATM inhibitor for 72h is shown as an example. 
 
 M
at
er
ia
ls
 a
n
d
 m
et
h
o
d
s 
39 
 
2.4 STRUCTURED ILLUMINATION FLUORESCENCE MICROSCOPY 
Structured illumination microscopy is a method of improving the resolution and out-
of-focus rejection in a conventional microscope. Instead of expensive laser-scanning 
and spinning-disc methods of traditional confocal microscopy, a single-spatial-
frequency grid pattern of projected light is used to create high resolution optical 
sectioning of the specimen192. Differential interference contrast (DIC/Nomarski) is a 
microscopy technique in which the difference in optical path length between two 
states of polarized light is used to enhance the contrasts of a transparent specimen. 
Cells from fixed or unfixed samples were either sorted by FACS directly onto a glass 
slide, or samples were spun at 1500g for 4 minutes before supernatant removal and 
they were transferred onto glass slides. All samples were mounted immediately after 
fluid condensation by ProLong Gold Mounting media. Coverslips of 0.17mm was 
used to avoid spherical aberrations. Tables of specifications of all primary and 
secondary antibodies used in this section can be found in the appendix.  
An Axio Z1 Imager microscope was used for immunofluorescence imaging and DIC 
microscopy of cells. This microscope was equipped with an ApoTome (enabling 
structured illumination) and a 120W Hg metal halide lamp (all Carl Zeiss, 
Oberkochen, Germany). DNA was detected using Hoechst 33258 fluorescence. 
Antibodies towards the nuclear envelope (LaminB2) and DNA DSBs (γH2AX) were 
both detected by FITC fluorescence, and these two parameters were not stained for 
simultaneously. Mitotic cells were stained for by an antibody against pHistone H3, 
and detected by PE fluorescence. Apoptotic cells were stained with a streptavidin 
linked Cy5 fluorochrome for biotin-dUTP incorporation after the TUNEL assay. To 
avoid photobleaching during imaging, the cells were illuminated with decreasing 
wavelengths, e.g. the last parameter to be imaged was DNA (UV light for Hoechst 
excitation). The filter sets used during microscopy are listed in table 2-1. 
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Table 2-1: Fluorescence microscopy filter set specifications. HE abbreviates High Efficiency 
and BP abbreviates Band Pass filter.  
A 63x oil immersion-objective with numerical aperture of 1.4 (0.2µm resolution) was 
used for all microscopy of fixed cells. For unfixed cells, a 40x air immersion-objective 
with a numerical aperture of 0.95 (0.3µm resolution) was employed. For visualizing 
multinucleated cells (LaminB2) each image field was optically sectioned into five 1.5 
µm thick slices, for counting γH2AX foci each field was sectioned into seven slices of 
1.0µm. AxioVision LE software (Carl Zeiss), version 4.5, was used to process the 
microscopy images.  
2.5 CELL COUNTING 
2.5.1 COULTER COUNTER 
Coulter counting is an efficient way of calculating the cell concentration in a cell 
suspension. The Coulter Counter-principle is based on detecting electrical resistance 
changes between two electrodes in a conductive fluid on each side of a cylindrical 
aperture. Each change in resistance is caused by a particle transiently displacing the 
conductive fluid in the aperture, as a fixed volume of particles is brought through. In 
a dilute solution of particles, each particle changes the impedance between the two 
electrodes and this generates an electrical pulse 193. The height of the pulse is 
proportional to the volume of the particle 193-195. The exact relation between pulse 
height and actual particle volume is calibrated using a uniform bead solution of 
known bead volume. 
A Z2 Coulter Counter (Beckman Coulter, Brea, CA) was utilized for growth 
assessment and reseeding calculations, both during routine cell culturing and during 
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all the experiments with molecular inhibitors. An amount of thoroughly mixed cell 
culture was diluted to appropriate counting concentration in physiological saline 
solution (NaCl 0.9%). The range for appropriate counting concentration was 
determined by the noise threshold and the highest tolerable chance of coincidence. 
The noise threshold was determined by five replicates of counting a solution of pure 
media diluted in the same manner as each sample. The threshold value average was 
114 counts with a standard deviation of 10, whereas the lowest cell count measured 
in a sample was 6500 counts. The term coincidence refers to event of two particles 
entering the aperture at the same time. In that case, two discrete particles will be 
measured as one particle with the combined size of the two particles. The chance of 
coincidence was calculated from the concentration of the particle solution and 
automatically corrected for in the Coulter Counter.  
2.5.2 BD LIQUID COUNTING BEADS 
A liquid suspension of fluorescent microspheres, BD Liquid Counting Beads (an 
addition to the BD viability kit) enables cell counting. The principle of these beads is 
that a relative concentration of cells can be determined in a solution with a known 
bead concentration using flow cytometry. To test the reliability of the method, all 
Coulter counted cell samples was also analyzed with this counting method. The BD 
Liquid Counting Beads solution has an accurate bead concentration, and cell samples 
with unknown cell density was added a fixed volume of 50µl BD Liquid Counting 
beads. The sample volume was 0.5ml for all Reh and U698 samples and 1.0ml for 
JVM-2 and Granta-519 samples due to the differences in initial cell concentrations. 
To acquire reliable data for all samples, a stopping gate of 5.000beads was chosen. 
This ensured a minimum cell count of 10.000cells for the samples with the lowest 
cell concentrations. The beads and bead doublets was clearly distinguishable from 
cells in a plot of side scatter against forward scatter. Figure 2-3 A, in section 2.3.1, 
illustrates a typical example of the population of beads and cells. 
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The concentration of cells in the sample was calculated using equation [1]. 
 
An ordinary linear regression was performed to establish the correlation between 
the Liquid Counting Beads and Coulter counting (figure 2-5). 
 
Figure 2-5: Ordinary linear regression of cell concentration assessment in the same samples 
with Coulter Counter and BD Liquid Counting Beads 
2.6 WESTERN BLOTTING 
For detailed specifications of all primary and secondary antibodies, as well as 
recipes used this section, see appendix. 
Protein lysates for western blotting were prepared by adding 100µl 2x loading 
buffer (0.125M Tris-HCl, 5mM DTT) directly to cell pellets consisting of 500.000 
cells. The loading buffer contains 4% Sodium dodecyl sulfate (SDS). The negatively 
charged SDS molecules will coat the denatured proteins according to size. A 
glycerol content of 20% and 0.1% Bromophenol Blue in the loading buffer, will 
ensure eased and more secure loading into running buffer-submerged wells. 5-
10 U/ml Benzonase, 0.025-0.05 TIU/ml Aproteinin and 0.1% of phosphatase 
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inhibitor cocktail II and III were added to the loading buffer to reduce sample 
viscosity, proteolysis and phosphatase activity respectively.  
The cells were both chemically lysed by the detergents in the loading buffer 
(mainly SDS and DTT) and mechanically lysed by pipetting on ice, vortexing for 5 
minutes and, finally, by heat denaturation at 95°C for 7 minutes. Samples were 
stored at -20°C and used within a two-week period. 
SDS-Polyacrylamide Gel Electrophoresis (PAGE) was used to separate the SDS-
coated proteins in the lysates by size. First, an 8% polyacrylamide gel with a 
standard Tris/Hepes-running buffer was employed, but the phospho-ATM 
protein band at 370kDa was barely visible and blurred. Separation and blotting 
of this large protein was successfully improved by using a 7.5% polyacrylamide 
TGX-gel from Bio-Rad with the supplied Tris/Glycine/SDS-running buffer. SDS-
PAGE was performed at 150V for 1h. When an electric current is applied to the 
gel, the negatively charged SDS-coated proteins will be trapped and 
concentrated between the chlorides and the glycine in the first part of the gel 
(stacking gel), before the pH changes in the separating part of the gel and the 
zwitterion glycine shifts charge to positive. To assess the size of the proteins 
after SDS-PAGE, a dual colored protein standard of known size (kDa) was applied 
to at least two separate wells of each gel. 
The negatively charged, separated proteins were transferred from the gel to a 
methanol activated polyvinyldifluoride (PVDF)-membrane (pore size 0.45 µm), 
during an overnight electro-blotting procedure at 15V in transfer buffer 
(20%methanol, 0.02M Tris-HCl, 0.2M Glycine) at 4°C. The PVDF-membrane was 
preblocked in a 5% dry milk solution of TBS (Tris-buffered saline) with 0.05% 
Tween 20 (TBS-T) for 1h, before incubation with primary antibodies diluted in 
TBS-T. The membrane was cut horizontally between the 75 and 100kDa protein 
standard bands, the upper part was incubated with 1:1000 anti-phospho-ATM 
(Ser1981), the lower part was incubated with 1:1000 anti-phospho-CHEK2 
(Thr68) and 1:5000 anti-TUBG2 (γTubulin). Incubation of the membrane with 
primary antibodies was done overnight at 4°C, before the excess antibodies 
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were washed from the membrane in three times TBS-T for 5 minutes. Species-
specific secondary antibodies conjugated with horseradish-peroxidase (HRP) 
were incubated 1:10.000 in 5% dry milk TBS-T for 1h before the same wash 
procedure was performed.  
To detect the protein bands on the membrane, enhanced chemiluminescence 
(ECL)-detection was used. Photons are released by oxidization of luminol, as 
hydrogenperoxide is reduced by the HRP-enzyme. The HRP-linked antibody is 
again bound to the proteins of interest. Light emitting from the 
chemiluminescent substrate stained a photosensitive Amersham Hyperfilm ECL 
(GE Healthcare, Little Chalfont, UK). The film was developed in a Curix 60 
automatic developer (Agfa, Greenville, SC), and scanned using a GS800 scanner 
(Bio-Rad, Hercules, CA). 
2.7 CALCULATION OF CELL CYCLE PHASE DURATIONS  
The age distribution in the mitotic cell cycle is not uniform because one cell at cell 
cycle completion always divides into two newborn daughter cells. Consequently, the 
proportion of the duration of one cell cycle phase is not equal to the proportion of 
cells in that particular phase. The relative proportion of cells of any cell cycle age 
decreases exponentially with increasing cell cycle age. To calculate the duration of 
each cell cycle phase in a population, a function of cell cycle age frequency was 
derived. Relative frequency of cells at different cell cycle time points in an 
exponentially growing population can be defined by the function [2]:  
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A normalized time parameter was defined to make the function as universal as 
possible, excluding differences in total cell cycle duration between different cell 
systems: 
 
Under the assumption of an ideal, asynchronous population during exponential 
growth, the frequency of cells at time zero will always be twice the frequency of cells 
at cell cycle completion. To ensure this premise, the negative constant k must satisfy:
Integration of the relative frequency of cells as a function of t’ yields the fraction of 
cells between given time points in the cell cycle. To ensure a total cell fraction of one 
in the definite integral from time=0 until time=Tc, a normalization of N(0) is required: 
 
The final equation [3] describing cell cycle time and cell frequency is illustrated in 
figure 2-6:
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Figure 2-6: Distribution of cells in an ideal, asynchronous population of proliferating cells. 
Cell cycle phase areas defined by 47% cells in G1, 42% in S, 6% in G2 and 2% in mitosis (M). 
The shape of the distribution is given by function [3].  
The total cell cycle duration was assumed equal to the doubling time, and was 
calculated by the mean cell counts. Thereafter, function [3] was used to calculate the 
lengths of the cell cycle phases from the mean cell cycle fractions after three 
replicates of 24h incubation with PARPi and ATMi.  
2.8 CALCULATION OF ADDITIVE EFFECT 
Determination of additive effect of combining two drugs in the same cell system 
requires advanced calculation if both drugs have an effect on the system. Simple 
calculation of potentiation and enhancement can be used if one drug does not have 
an effect by itself, but increases the effect of the other drug. According to the Chou-
Talalay method, calculation of whether the combination of two drugs has a 
synergistic (more than additive), additive or antagonistic (less than additive) effect, 
requires testing of at least three appropriate concentrations of each drug alone and 
in combination196. However, the combined effect (E1+2) of two mutually non-
exclusive drugs (1 and 2), as expected for ATMi and PARPi, can be described by the 
simple function [4]:   
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The equation can be rewritten as: 
 
This equation shows that the combination curve and the dose response curve of the 
single drug are in parallel in a logarithmic plot. In the case of this study, the total 
effect of PARPi and ATMi is additive if this curve is in parallel with the PARPi curve in 
a logarithmic dose response plot. 
2.9 STATISTICAL METHODS 
Standard Error of the Mean (SEM) has been used throughout this thesis to describe 
the variation in the expected mean of repeated measurement-series. Standard 
deviation (SD) was only used to describe the variation between measurements using 
a particular method. Ordinary linear regression was performed with version 18.0 of 
SPSS (IBM, Armonk, NY). 
 
 
 
 
 
 
 
 
 
 R
es
u
lt
s 
48 
 
3 RESULTS  
3.1 CELL DEATH AND PROLIFERATION AFTER PARP AND/OR ATM 
INHIBITION 
Cell death and total cell numbers were measured during a 72h-period after addition 
of PARP inhibitor (PARPi) and/or ATM inhibitor (ATMi). Before proceeding with these 
experiments, we first wanted to determine the functionality of ATM in these cell 
lines. If present and functional, ATM is autophosphorylated at serine 1981 after e.g. 
X-irradiation44. Immunoblotting showed that ATM became strongly phosphorylated 
in Reh, U698 and JVM-2 cells 1h after irradiation with 4Gy (figure 3-1). However, 
some phospho-ATM (pATM) was also induced in Granta-519 cells, although these 
cells have been reported to have defective ATM function179,180. If cells were 
irradiated in the presence of ATMi, phosphorylation was reduced, but not entirely 
back to control levels. The downstream ATM-target CHEK2 was also analyzed, and 
the phosphorylation of threonine 68 of CHEK2 (pCHEK2) levels varied in the same 
manner. 
 
Figure 3-1: ATM autophosphorylation and phosphorylation of downstream ATM target 
CHEK2 in unirradiated, irradiated and ATM inhibited and irradiated Reh, U698, JVM-2 and 
Granta-519 cells. Samples were lysed 1h post-4Gy, and an irradiated sample of each cell was 
added 10µM ATM inhibitor 15 minutes prior to irradiation. Loading control was TUBG1 
protein amount displayed in the last row. 
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The fraction of dead cells was assessed by the PI/TO assay and was below 5% in 
control Reh and U698 cells, and 8-13% in control JVM-2 and Granta-519 cells during 
the time course of the experiment (figure 3-2). Treatment with ATMi alone did not 
induce more cell death than in the control.  
 
Figure 3-2: Fraction of dead cells as a function of PARP and/or ATM inhibitor treatment 
duration for Reh, U698, JVM-2 and Granta-519 cells. Mean value from three independent 
experiments ±SEM. 
Treatment with PARPi alone at varying concentrations did not increase the fraction 
of dead cells, the exception being for the highest concentration (3μM) in Reh, JVM-2 
and Granta-519, and a slight increase for Granta-519 after incubation with 1μM. 
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However, cell death caused by inhibition of PARP by the three different 
concentrations of PARPi was increased from control levels in the presence of ATMi, 
indicating enhancement of the effect of PARP inhibition by inhibition of ATM 
(synthetic lethality). The exception was Reh cells treated with 0.3μM PARPi and ATMi 
(figure 3-2). 
The dose response curves for cell death at 72h as a function of PARPi concentration 
are shown in figure 3-3. Inhibition of ATM caused an increase in cell death for Reh, 
U698 and JVM-2 cells for all concentrations of PARPi. This effect was much less 
pronounced for Granta-519, which only showed a small increase in cell death caused 
by ATM inhibition at 0.3 and 1.0μM PARPi. 
 
Figure 3-3: Dose response curves of cell death in Reh, U698, Granta-519 and JVM-2 as a 
function of PARP inhibitor concentration after 72h treatment with/without 10µM ATM 
inhibitor. Mean value from three independent experiments ±SEM. 
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Total cell numbers were assessed by Coulter counting. The number of viable cells 
was calculated from the raw data after subtraction of the number of dead cells 
(figure 3-4). Growth was close to exponential in control cultures. Although treatment 
with ATMi alone did not increase the fraction of dead cells (figure 3-2), a decrease in 
live cell numbers was observed at all time points in all cell lines, indicating that the 
ATM inhibition caused an increased cell cycle time. 
Inhibition of PARP in the absence of ATMi decreased the number of cells at 48-72h in 
a dose-dependent manner (figure 3-4). At 0.3μM, this reduction was only significant 
for JVM-2. Additionally, the growth curves after treatment with 3μM PARPi were not 
exponential at the later time points. This is to be expected if cell death becomes 
more extensive, which was observed for Reh, JVM-2 and Granta-519 (figure 3-2). 
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Figure 3-4: Cell growth during PARP and/or ATM inhibitor treatment in Reh, U698, JVM-2 
and Granta-519 cells. Live cell number is plotted as a function of treatment duration. Mean 
value from three independent experiments ±SEM. 
When cells were treated with ATMi in addition to PARPi, the cell numbers decreased 
further, but this reduction was not significant for Granta-519 at 3μM PARPi. The cell 
numbers tended to decrease from 48 to 72h after treatment with ATMi and 3μM 
PARPi (figure 3-4); at this time, there was pronounced cell death for all cell lines 
(figure 3-2). If a simple model for additive effect is applied (see section 2.8), the 
dose-response curves in the absence and presence of ATMi should be parallel (figure 
3-5). This was the case for Granta-519. However, for the other cell lines, and 
particularly for U698, the diverging curves indicated that the total effect of the two 
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inhibitors was larger than the sum of the individual treatments, i.e. the effect was 
synergistic. 
 
Figure 3-5: Dose response curves of relative live cell numbers in Reh, U698, Granta-519 and 
JVM-2 as a function of PARP inhibitor concentration after 72h treatment with/without 10µM 
ATM inhibitor. Mean value from three independent experiments ±SEM. 
3.2 PARP AND ATM INHIBITED GRANTA-519 AND REH CELLS DIE BY 
APOPTOSIS 
 
Apoptosis was measured by TUNEL-assay (DNA fragmentation), but also confirmed 
during fluorescence microscopy as all the observed TUNEL-positive cells had typical 
morphological characteristics associated with apoptosis. Cells which were TUNEL 
positive were in general smaller than average, some had undergone membrane 
 R
es
u
lt
s 
54 
 
blebbing, and apoptotic bodies were observed. It is difficult to determine by 
microscopy whether an apoptotic cell originates from an interphase cell or a mitotic 
cell. However, a distinct peak of apoptotic cells likely to be tetraploid, strongly 
suggested that the cells initiated apoptosis from G2 or mitosis. 
Apoptotic fraction in the mock-treated cell samples was below 1.5% in Reh and U698 
cells, below 4% in JVM-2 cells and below 6% in Granta-519 cells (figure 3-6). 
Treatment with PARPi alone induced no increase in apoptosis in U698 cells 
compared to control. However, a slow increase, most pronounced at 48h and 72h, 
was observed in 3µM PARPi treated Reh and JVM-2 cells. ATM inhibition alone did 
not cause significant increases in apoptosis in Reh and U698 cells, but a slight 
elevation in JVM-2 and up to 3% increase in Granta-519. A rapid increase in 
apoptotic levels was observed in Granta-519 cells at all three PARPi concentrations. 
The combined PARPi/ATMi treatment increased the apoptotic fractions compared to 
PARP inhibition alone. However, the apoptotic fractions were below 4% and 11% for 
U698 and JVM-2, respectively. There was a large, but again delayed, increase in 
apoptosis in Reh cells caused by the additional treatment with ATMi. The apoptotic 
fractions of Granta-519 cells also increased in the presence of ATMi, but the effect 
was not as pronounced, and not significant at 3μM PARP inhibition for 72h. 
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Figure 3-6: Apoptosis measured by TUNEL assay in Reh, U698, JVM-2 and Granta-519 cells 
during 72h treatment with PARP and/or ATM inhibition. Apoptotic fraction is plotted as a 
function of treatment duration. Mean value from three independent experiments ±SEM. 
The dose-response curves for apoptosis after 72h treatment revealed an 
enhancement of approximately threefold in Reh cells (figure 3-7). A synthetic lethal 
interaction between the two drugs was seen in Reh cells, since there was no effect of 
ATMi alone. In contrast, the apoptotic fractions of the presumably ATM-deficient 
Granta-519 cells (figure 3-1) were only 50% enhanced by ATMi (at 0.3µM PARPi). 
This increase was also observed with ATMi alone, resulting in almost parallel dose-
response curves in the absence and presence of ATMi. The dose-response curves for 
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U698 and JVM-2 suggested some enhancement by ATMi, but the effects of 
treatment on apoptosis were far less pronounced than on cell death (figure 3-3).
 
Figure 3-7: Dose response curves of 72h treatment with PARP inhibitor and/or 10 µM ATM 
inhibitor on induction of apoptosis. Mean value of single, TUNEL positive cells ±SEM. 
Ordinary Linear Regression (OLR) of cell death as a function of apoptosis for all 
treatments at all time points for the four cell lines (figure 3-8), revealed that the 
dead cell fractions were almost three times (slope of regression lines/regression 
coefficients) higher than the apoptotic fraction in the same samples of U698 and 
JVM-2 cells. The regression coefficient in Granta-519 cells was not significantly 
different from 1.0.  
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Reh cells showed the same trend as Granta-519, but the slope of 1.39 was 
significantly different from 1.0 (95% CI of 1.23-1.54). Since there are few data points 
at the high levels of apoptosis and cell death for Reh, the regression is heavily 
influenced by those points without regard for the insecurity of the measurement. 
More observations of severe cell death and apoptosis in Reh cells (e.g. new 
experiments with expanded treatment duration) could be performed to test the 
validity of the current slope. OLR results for each cell line are attached in the 
“Calculations” section in the appendix. 
 
Figure 3-8: Ordinary linear regressions of dead cell fraction as a function of apoptotic cell 
fraction in the 24 differentially treated samples of PARP and/or ATM inhibited Reh, U698, 
JVM-2 and Granta-519 (mean values from three independent experiments). The dotted lines 
represent the 95% confidence interval of the regression coefficient. 
Hence, Reh and Granta-519 cells died by apoptosis after PARP inhibition, while JVM-
2 and U698 cells mainly died by necrosis (further evaluated in sections 3.6 and 3.7). 
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3.3 DNA DAMAGE IN S PHASE INCREASE BY PARP INHIBITION 
To assess the amount of DNA double strand breaks occurring as a result of PARP 
inhibition, we measured the closely correlated intensity of phosphorylated Serine 
139 on histone H2AX (γH2AX) by flow cytometry197. However, antibody binding 
varied with cell number, and normalization of the data was required. It was observed 
that secondary antibody background was highly dependent on cell number as shown 
in figure 3-9 A (approx. 1.5 million stained cells) and B (approx. 300.000 stained 
cells). This background increased linearly with increasing DNA content. Untreated 
cells have been shown to have a bimodal γH2AX-distribution due to cell cycle specific 
DSBs and subsequent repair37,39. PARP inhibition induced phosphorylation of γH2AX 
in a cell cycle specific manner, and the γH2AX levels increased during S and partially 
in the G2 phase (figure 3-9 A and B). There were no local variations in intensity 
during S phase, and we therefore assessed γH2AX content in mid-S to avoid 
contributions from G1 and G2/M. In contrast, X-irradiated cells will acquire DSBs 
independently of position in the cell cycle. As the DNA content in mid S is 1.5 times 
that of G1, this is consistent with the observed 1.5-fold increase in γH2AX intensity in 
mid-S phase compared to G1 in the irradiated sample (figure 3-9 C) 
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Figure 3-9: Flow cytometry analysis of γH2AX staining intensity in Granta-519 cells exposed 
to vehicle alone (A) or 10µM ATM inhibitor and 3µM PARP inhibitor (B) for 72h or 1h post-
irradiation of 4Gy (C). Staining with secondary antibody (2˚Ab) alone is shown in black/white 
for A and B. Upper row shows two parameter dot plots of γH2AX against DNA content, while 
the lower row shows the γH2AX intensity histograms for the same samples. 
The bimodal γH2AX distributions suggest that the fluorescence of the G1 cells was 
due to non-specific staining. We sorted cells according to DNA and pHistone H3 
content by flow cytometry and inspected them by fluorescence microscopy for the 
characteristic γH2AX foci in cells with DSBs198. Most G1 cells had no foci; some had 
one γH2AX focus, and a few had two foci (figure 3-10). The γH2AX intensity of G1 
cells by flow cytometry should thus reflect background staining. Assuming that the 
background of the primary antibody varied in the same manner as the secondary, we 
normalized the flow cytometry data for S and M phase cells to the G1 intensity as 
described in 2.3.3. S phase cells had multiple foci both in treated and untreated 
samples, although the variation in number of foci was higher in the untreated 
samples, and the mean focus number was higher in the treated samples. This was in 
agreement with the internally varying intensities of γH2AX in control S phase cells 
(figure 3-9 and figure S4 in the appendix) and the higher intensity of treated S phase 
cells by flow cytometry, respectively (figure 3-11 and figure S4 in the appendix). G2 
cells showed a bimodal γH2AX distribution, which was most pronounced for JVM-2 
and Granta-519 (figure S4 in the appendix). The bright G2 cells are probably the ones 
that most recently left S phase and have not yet repaired the damage inflicted in S 
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phase. Most of the G2 cells with low γH2AX content had no foci, with some cells 
having one or two foci (figure 3-10), reminding of the distribution seen in G1 cells. 
Mitotic cells showed strong and diffuse staining, although they rarely contained foci. 
 
Figure 3-10: Fluorescence microscopy images of Granta-519 cells treated with 10µM ATM 
inhibitor and 1µM PARP inhibitor for 48h. The cells were sorted on DNA content and 
pHistone H3 status prior to microscopy. 
The normalized γH2AX level in mid-S phase of the untreated samples was found to 
be 1.5-3.5 times the amount in G1 (figure 3-11), which is in agreement with previous 
studies37. In contrast to this, the normalized γH2AX level in mid-S phase cells after IR 
was close to 1.0 (figure 3-9). PARPi alone increased the amount of DNA DSBs in S 
phase in a dose dependent manner for all cell lines. ATMi had no significant effect 
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alone in Reh or Granta-519 cells, but increased γH2AX for JVM-2 and U698 cells. 
Combined PARP and ATM inhibition did not enhance or alter the effect of PARP 
inhibitor treatment in Reh and Granta-519, and the trend for U698 cells is actually a 
decrease in induction of γH2AX with increasing PARPi concentration, while JVM-2 
cells had less systematic changes. 
 
Figure 3-11: γH2AX intensity in mid-S phase cells during 72h PARP and/or ATM inhibitor 
treatment. The fold change of γH2AX intensity in mid S phase was normalized by DNA 
content (1.5) and the intensity of G1 phase in the same sample (three experiments, ±SEM). 
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Mitotic cells in this cell line panel displayed high γH2AX intensity even in the 
untreated samples (figure 3-12). This was in good agreement with the results from 
fluorescence microscopy (figure 3-10), showing that the pHistone H3 (Ser10) positive 
cells had diffuse and strong γH2AX staining. DNA DSBs should cause focal staining, 
and such foci have been observed in cells that enter mitosis after ionizing radiation38. 
Additionally, substantial and non-focal γH2AX induction in mitosis have previously 
been found to be independent of DNA damage199. The relative γH2AX content in 
mitotic cells did not increase after treatment with either of the inhibitors alone or in 
combination (figure 3-12). In contrast to the S phase results, the mitotic cells 
displayed a trend of decreasing intensity with increasing PARPi concentration.   
 
Figure 3-12: γH2AX intensity in pHistone H3 positive cells during 72h PARP and/or ATM 
inhibitor treatment.  The fold change of γH2AX intensity in mitotic cells was normalized by 
DNA content (2.0) and the intensity of G1 cells in the same sample (three experiments, 
±SEM). 
PARP inhibition induced about half the amount of DNA damage as 4Gy of ionizing 
radiation induced in Granta-519 cells (figure 3-9).  
 R
es
u
lt
s 
63 
 
3.4 ATM INHIBITION INDUCES MITOTIC DELAY IN                               
U698 AND GRANTA-519 
The mitotic fraction was assessed by immunostaining of pHistone H3 (Ser10). In 
U698 and to some degree in Granta-519 the ATMi alone caused an increase in the 
mitotic fraction (figure 3-13). We have previously observed that the ATMi (KU-
55933) is able to create this phenotype in U698 cells82. PARP inhibition reversed this 
effect in a dose dependent manner for U698 and Granta-519 cells. The doubling time 
increased somewhat in the presence of ATMi (figure 3-4), and the transition time 
through mitosis thus increased even more. Although the mechanism for this delay is 
unclear, it may contribute to the growth inhibiting effect of ATMi alone in these cell 
lines. With only a few significant changes in mitotic fraction, PARP and/or ATM 
inhibition had no systematic effect on the mitotic of Reh and JVM-2 cells (figure 3-
13). 
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Figure 3-13: pHistone H3 (Ser10) positive fraction of single non-apoptotic Reh, U698, JVM-2 
and Granta-519  cells during 72h treatment with PARP inhibitor and/or 10μM ATM inhibitor. 
Mean value is derived from three independent experiments ±SEM. 
3.5 PARP AND ATM INHIBITION CAUSES G2-PHASE DELAY 
Cell cycle distribution analysis is a static snapshot of a dynamic process. The 
distribution does not give information about the duration of the cell cycle. 
Moreover, it will not be altered in the event of simultaneous arrest/delay of the 
whole population. As PARP and ATM inhibition caused low and in some cases 
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negative cell growth rates (figure 3-4), we needed to address whether or not the 
cells were actually cycling. The mitotic fraction was not changed significantly by 
PARP inhibition alone (figure 3-13), indicating that this treatment did not cause a 
disproportional increase in mitotic transition time. The flux of cells into mitosis was 
monitored by adding the microtubule polymerization-inhibitor nocodazole 6h prior 
to harvest after 24h and 72h (figure 3-14) incubation with 3 μM PARPi and/or ATMi. 
This stathmokinetic experiment demonstrated that cells were passing through 
mitosis in all the samples. The amount of cells trapped in mitosis by nocodazole was 
reduced by PARP inhibition, consistent with an increased doubling time at 24h 
(figure 3-4). 
 
Figure 3-14: Nocodazole induced mitotic arrest during 18-24h and 66-72h of PARP and/or 
10μM ATM inhibition. The controls were harvested at 24h and 72h. 
Cell cycle analysis by flow cytometry revealed that the cell cycle distributions in 
control samples varied somewhat between the cell lines (figure 3-15). Most notably, 
Reh cells differed from the three other cell lines by having a lower G2 fraction and no 
cells with >4n DNA content. 
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Only small changes in cell cycle distribution were observed after ATM inhibition, 
notably an increase in mitotic fraction (in U698 and Granta-519) discussed in section 
3.4. Inhibition of PARP resulted in a dose-dependent increase in the G2 fraction, 
except for JVM-2 cells. Additional treatment with ATMi increased the G2 fraction 
compared to PARP inhibition alone, but not for Granta-519 cells. The fraction of 
U698 cells with >4n DNA content also increased upon PARPi treatment (in a dose- 
and time-dependent manner), and this effect was further enhanced in the presence 
of ATMi. In Granta-519 and JVM-2 cells the fraction of cells with >4n DNA content 
did not increase with PARP and/or ATM inhibition. The treatment-induced decrease 
in G1 fractions is only relative, as it will be shown later that the G1 transition time (at 
24h) was almost constant (figure 3-17). 
The dose-response curves revealed that ATMi-enhancement of PARPi effect on G2 
fractions was most pronounced in Reh followed by U698 cells (figure 3-16). PARPi 
was tenfold potentiated by the ATMi in Reh cells, as 3µM PARPi alone created the 
same effect as 0.3 µM PARPi combined with ATMi. While the y-fold enhancement 
increased with PARPi concentration for Reh cells (up to threefold), maximum 
enhancement was achieved in U698 cells at 0.3µM PARPi. In JVM-2 cells, the 
enhancement was less pronounced, and only significant after incubation with 1 and 
3µM PARPi. The ATMi alone caused a small enhancement of the effect of PARPi in 
the Granta-519 cell line.  
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Figure 3-15: Cell cycle analysis of single non-apoptotic Reh, U698, JVM-2 and Granta-
519 cells during 72h treatment with PARP- and/or 10µM ATM inhibition. Mean 
values from three independent experiments ±SEM. 
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Figure 3-16: Dose response curves of the effect of 72h treatment with PARP and/or ATM 
inhibition on accumulation of cells in G2 phase. Mean value from three independent 
experiments ±SEM. 
Cell cycle phase durations were calculated from the increases in cell numbers and 
the cell cycle distributions at 24h (figure 3-17). Later time points had to be excluded 
as cell death and endoreduplication (further discussed in 3.6 and 3.7) became so 
pronounced that cell cycle durations would have been overestimated. The cell cycle 
duration is close to 24h for all control samples. ATMi alone increased the doubling 
time with 2-9h, and delayed G1 for all cell lenes. The increase in G2 phase duration 
after PARP inhibition was striking for Reh and U698, but less so for JVM-2 and 
Granta-519 cells. This effect was further increased with additional treatment with 
ATMi. S phase was also prolonged in all cell lines. Especially PARPi increased the 
duration of S phase. There were only small changes in the length of G1 and mitosis.  
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Figure 3-17: Cell cycle durations (h) for Reh, U698, JVM-2 and Granta-519 after 24h PARP 
inhibitor and/or 10µM ATM inhibitor treatment. Mean cell cycle phase durations (h) are 
listed in the table below the column chart of each cell line. The G2 fraction and the 
calculated cell cycle phase durations could have been overestimated for the samples in 
which failed cytokinesis was observed at later treatment times (marked with an asterix). 
Moreover, extensive cell death may lead to overestimation of the lengths of cell cycle 
phases, as dead cells are not part of the growth fraction. Samples with significant increase in 
apoptosis and/or necrosis at 24 hours are marked with a cross. 
3.6 U698 CELLS DIE BY NECROSIS AFTER EXTENSIVE 
ENDOREDUPLICATION 
U698 cells displayed low levels of cell death and apoptosis after 72h (figures 3-2 and 
3-6). However, the highly pronounced effect on cell growth and especially the 
increase in cells with DNA content exceeding 4n (figure 3-15), indicated that U698 
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cells may respond to the treatment in a different manner. To reveal the fate of these 
cells, we extended the treatment of U698 cells to 144h. 
Cell cycle analysis of U698 cells after 144h inhibition of PARP and ATM confirmed 
that endoreduplication was extensive, and 62±6% of the cells had DNA content 
above 4n (figure 3-18; the peak annotations were confirmed by a mixture with 
diploid control cells, see figure S2 in the appendix). Diploid cells only accounted for 
4.5±2.8% of the single non-apoptotic cells. Thus, almost all treated cells eventually 
fail to complete cytokinesis. A cell with DNA content of 4n can represent either a 
tetraploid G2 cell or a binucleated post-mitotic cell. This makes calculation of the 
length of the cell cycle phases at these times more complicated. However, the shift 
in ploidies from 72 to 144h (figure 3-18) in the combined ATM and PARP inhibited 
sample indicated a duration of the endoreduplication cycle of the same magnitude 
as the perturbed cell cycle from 0-24h (figure 3-17). Flow cytometry analysis of the 
sample treated with both inhibitors for 144h revealed pHistone H3 positive cells with 
8n and 16n DNA content, and pHistone H3 positive cells about 15-20µm in size were 
also observed during fluorescence microscopy of this sample (see appendix, figure 
S3). 
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Figure 3-18: DNA histograms of single, non-apoptotic U698 cells treated for 72h or 144h 
with 3μM PARP inhibitor and/or 10μM ATM inhibitor. Fraction of cells with more than 4n 
DNA content (inset in each histogram) is represented in the 144h time point by the mean 
value of two replicate experiments ±range, and for the 72h time point the mean value is 
given by three independent replicates ±SEM. 
The cell numbers did not increase from 72h to 144h in the presence of ATMi/PARPi 
(figure 3-19 A), which is expected if the bulk of the cells endoreduplicate. More than 
60% of the cells had DNA content above 4n at this time (figure 3-19 B). Cell death 
also increased from 17% at 72h to 26% at 144h (figure 3-19 C). Quantification of 
apoptotic cells by the TUNEL-assay in endoreduplicating cells is not straightforward. 
Fragmented apoptotic bodies from one cell that died with 8n DNA content is 
undistinguishable from intact apoptotic cells with 4n or 2n DNA content. 
Nevertheless, TUNEL-positive cells with DNA content of 16n were present, indicating 
that at least some of the endoreduplicating U698 cells died by apoptosis, such cells 
were also observed during microscopy (figure S3 in the appendix). Both cell death 
(>25%) and the number of cells endoreduplicating (instead of dividing) explained the 
lack of increase in cell number in U698 after treatment with PARPi and ATMi (figure 
3-19). 
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Figure 3-19: Live cell numbers (A), fraction of single, non-apoptotic U698 cells with DNA 
content above 4n (B) and dead cell fraction of U698 cells during 144h incubation with 3μM 
PARP inhibitor and/or 10 μM ATM inhibitor (C). The time point at 144h is the mean of two 
replicate experiments ±range, for the 0-72h time points the mean value is given by three 
other independent replicates ±SEM. 
Fluorescence microscopy of U698 cells treated for 144h with both PARPi and ATMi 
revealed that they had been going through several aberrant mitoses without 
cytokinesis, as they were mostly multinucleated (figure 3-20). These cells were also 
larger, approximately 20μm, compared to control cells which were about 10µm. 
Some multinucleated cells were also observed in the samples treated with 3µM 
PARPi alone, consistent with the increase of cells with more than 4n DNA content of 
about 20% after 144h. 
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Figure 3-20: Fluorescence and DIC microscopy images of U698 cells treated for 144h with 
PARP inhibitor and 10µM ATM inhibitor. 
A few PARP and ATM inhibited U698 cells died by apoptosis, but the main death 
mechanism, after extensive endoreduplication, was necrosis. The heavily treated 
cells displayed phenotypes typical of mitotic catastrophe: Multiple nuclei and 
micronuclei. 
3.7 JVM-2 CELLS DIE BY NECROSIS AFTER MITOTIC CATASTROPHE  
JVM-2 cells showed significant decreases in cell viability after 72h PARP and ATM 
inhibition (figure 3-2), yet the level of apoptosis could not account for the cell death 
caused by the treatment (figures 3-4 and 3-6). Cell sorting on JVM-2 cells were based 
on the same criteria as when measuring cell death, namely uptake of a non-
permeable dye (in this case, Hoechst 33258). DIC and fluorescence microscopy 
(figure 3-21) was performed on the sorted JVM-2 cells after 48h inhibitor treatment. 
The dead cells had the appearance of necrotic cells. The cytoplasmic and nuclear 
membranes had ruptured, and DNA was no longer confined to the nucleus or even 
the cell. 
 R
es
u
lt
s 
75 
 
 
Figure 3-21: Microscopy images of Hoechst 33258 fluorescence and combined fluorescence 
and DIC microscopy of mounted, unfixed JVM-2 cells. After 48h treatment with 3µM PARP 
inhibitor and 10µM ATM inhibitor, live (Hoechst 33258 negative) and dead (Hoechst 33258 
positive) cells were sorted prior to microscopy. 
Immunostaining of the nuclear envelope component Lamin B2 revealed that many of 
the PARP and ATM inhibited JVM-2 cells were multinucleated, compared to the 
untreated control cells (figure 3-22). The increase in number of nuclei and cell size 
were not as extreme as for the endoreduplicating U698 cells (figure 3-20). The 
fraction of cells with DNA content above 4n did not increase with treatment in JVM-
2; they were therefore not able to enter a new S phase after having failed to 
complete cytokinesis. 
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Figure 3-22: Fluorescence microscopy images of JVM-2 cells treated for 48h with 3µM PARP 
inhibitor and/or 10µM ATM inhibitor. Each multinucleated cell is indicated by an arrow. 
 
 
 
 
 
 
 
 D
is
cu
ss
io
n
 
77 
 
4 DISCUSSION 
The discovery of synthetic lethality3 in cells with homologous recombination repair 
(HRR)-defects after treatment with PARP inhibitors1,2 spurred a rapid 
implementation of PARP inhibitors in cancer treatment. Originally, it was suspected 
that PARP inhibition led to impared repair of SSBs, which were converted into DSBs 
during replication. These DSBs was tought not be repaired by the HRR-deficient cells, 
and thereby cause cell death. However, the  amount of SSBs has not been found  to 
increase in response to PARP inhibition13,14. Hence, the proposed mechanism  of 
synthetic lethality was recently acknowledged to be inaccurate159. In this study we 
have demonstrated some of the phenotypes induced by  combined loss of activity of 
PARP and the HRR-initiating protein ATM. An automated staining procedure for 
combined assesment of γH2AX, DNA content, mitosis and apoptosis by flow 
cytometry was developed. Severe cell death, cell cycle progression delay and dose-
dependent induction of DNA DSBs was observed  during the three day continuous 
exposure to PARP and ATM inhibitors.   
Development of an automatic staining procedure by use of a microplate sample 
processor and microplate washer reduced the sample preparation time by 30-40%. 
The procedure minimized the strenuous and labor-intensive pipetting, supernatant 
removal and relocation of each tube both in and out of the centrifuge.  This 
procedure could possibly reduce occupational injuries (due to pipetting). In addition, 
hands-on time was lowered and the reagent-volumes could be minimized, thereby 
experiment-costs were reduced as well. 
We wanted to investigate PARP inhibition in ATM-deficient lymphoid cancer cells, as 
ATM deficiency is common in both MCLs16  and B-CLLs17. Chemically induced ATM 
deficiency was obtained with the ATM inhibitor KU-55933, and combined with the 
PARP inhibitor olaparib in the cancer cell lines Reh, U698, JVM-2 and Granta-519. 
The Granta 519 cell line was reported to be ATM-deficient179,180. Previous studies 
have shown a lack of functional ATM activity in this cell line based on the ATM 
autophosphorylation site Serine 19814,7,8. However, our immunoblotting of pATM 
(Ser1981) indicated some residual autophosphorylation of ATM in irradiated Granta-
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519 cells, yet less than for the other cell lines (figure 3-1). The phosphorylation of 
ATMs downstream target CHEK2 (Thr68) was consistant with the pATM results. All of 
the Granta-519 dose response curves in the presence of ATM inhibitor are in parallel 
or overlapping with the corresponding control curves (figures 3-3, 3-5, 3-7 and 3-16). 
Thereby, Granta-519 cells deviates from the three ATM proficient cell lines, 
indicating low effect of inhibiting the residual ATM function in Granta-519 cells. 
We anticipated no severe effect  by ATM inhibitor alone on the measured 
parameters in this study, based on our previous work with this inhibitor82. Our 
assumption was valid for cell death, apoptosis and cell cycle distribution in general. 
Cell line specific ATM inhibitor induced changes were observed in γH2AX S phase 
intensity (increased in JVM-2 and U698) and mitotic fraction (increased in U698 and 
Granta-519). Additionally, a marked increase in doubling time after ATM inhibitor 
treatment were seen in all cell lines (figure 3-2). Although, we have previously 
observered the effect of ATM inhibition on progression of mitosis82, our previous 
experiments were not carried out for enough time to observe the growth inhibiting 
effect. Another group have reported that the antiproliferative effect of ATM inhibitor 
was phenocopied by siRNA-mediated knockdown of ATM, suggesting that the effect 
is ATM specific200. ATM has lately been shown to activate Akt in response to insulin-
signalling201, DSBs202 and ionizing radiation201. Akt/PKB is known for inhibition of 
apototisis and promoting cell cycle progression, and Akt1 knockout mice display 
increased apoptosis and cell growth retardation203. The ATM inhibitor KU-55933 
generates the same phenotype in cancer cells204.  This may explain the results in this 
study and the fact that insulin resistance have been reported for 30 years in ataxia 
telangiestacia-patients205,206. Further investigations of the Akt pathway could 
demonstrate whether this is the cause of the growth inhibiting effect of ATM 
inhibition in our study.  
The durations og S and G2 was prolonged due to the treatment with PARP inhibitor 
and/or ATM inhibitor (figure 3-17). The stathmokinetic experiment with nocadazole 
(figure 3-14) confirmed that the cells were not arrested. As the length of G1 was 
relatively unchanged, while S phase was delayed by PARP inhibition, a likely cause 
would be an increased number of DNA DSBs caused by the treatment (figure 3-11). 
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Additional loss of ATM activity dramtically prolonged G2, consistant with the 
hypothesis that cells acquire problems repairing these DSBs in the absence of HRR. 
The range of γH2AX intensity in G2 for untreated and treated are more pronounced 
in JVM-2 and Granta-519 (bimodal distributions) than in Reh and U698 cells (figure 
S4 in the appendix). In addition, the most extreme G2 delay was seen in Reh and 
U698 cells (figure 3-16). The coinciding results of delay and γH2AX distribution in G2 
may reflect differences in the repair kinetics of these cell lines. While Granta-519 and 
JVM-2 cells may repair the damage rapidly, U698 and Reh cells may require more 
time to resolve the same amount of DNA damage. Thus, Granta-519 and JVM-2 
spend a larger fraction of their G2 phase in a γH2AX-negative state. Reh and U698, on 
the other hand, spend more time on repairing DNA and may be released into mitosis 
almost immediately after becoming γH2AX negative. The lack of focal γH2AX staining 
in PARP inhibited mitotic cells was treament independent (figure 3-10), supporting 
the view  that the cells must repair the damage associated with γH2AX foci in G2 
before mitotic entry. ATM and DNA-PK function redundantly to phosphorylate H2AX 
(Ser139) in response to DNA damage207. Non-damage related γH2AX induction in 
mitosis have previously been proposed to be ATM dependent as ATM-reconstituting 
a A-T cell line caused mitotic γH2AX expression, while DNA-PK-deficient cells 
displayed normal mitotic γH2AX-phenotype199. In contrast, our data showed high 
γH2AX levels in mitosis independent of ATM inhibition (figure 3-12). This 
inconsistency may be clarified by dual inhibition of DNA-PK and ATM in our cell lines. 
In this study, Reh and Granta-519 cells were found to die by apoptosis after PARP 
inhibition (figures 3-2 and 3-6). We have previously shown that U698 cells are 
resistant to irradiation-induced apoptosis, while Reh cells are not208. However, U698 
cells become apoptotic in response to being nutrient depleted in dense growing 
culture and to prolonged nocodazole treatment208. Thus, U698 cells have intact 
apoptotic machinery and the error must be in the upstream apoptosis-inducing part 
of the DDR signaling. Both the untreated and irradiated TP53-deficient U698 cells 
have elevated expression of anti-apoptotic protein MCL1209, and several studies 
show that apoptosis is avoided in TP53-deficient cells because of failure to degrade 
MCL1210,211. Our results of induction of apoptosis after PARP inhibition in Granta-519 
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cells are in agreement with studies by Williamson et al. (TUNEL , Annexin V and 
Western blots)4,9. Weston et al.7 reported negative results of Annexin V-staining and 
proposed mitotic catastrophe as main death mechanism of PARP inhibited Granta-
519 cells. Weston et al. argued that a mitotic catastrophe was pHistone H3 negative 
cells with loss of nuclear membrane integrity with Lamin B1-staining and multiple 
nuclei. 
Continuous ATM and PARP inhibition for 144h in U698 cells revealed that over 60% 
of the cells were multinucleated (figure 3-19) and  endoreduplicating, while only 
about 4% were in diploid G1 (figure 3-18). Microscopy of PARP and ATM inhibited 
JVM-2 cells revealed that they were largely multinucleated (figure 3-22), but they did 
not endoreduplicate (figure 3-15). Mitotic catastrophe followed by necrosis was the 
main death mechanism in U698 and JVM-2, as the number of apoptotic cells (figure 
3-6) was clearly outnumbered by dead cells (figure 3-2). Even though some of the 
multinucleated U698 and JVM-2 cells still were viable at the end of the experiments, 
they did not seem able to resume proliferation (i.e. they are not potentially 
malignant).  
In contrast to U698 cells, JVM-2 cells do not endoreduplicate in response to PARP 
and ATM inhibition. We have previously shown that U698 cells lack a functional G1/S 
checkpoint in response to IR208, and proposed that this is caused by loss of TP53. The 
role of TP53 in prevention of polyploidy and endoreduplication has previously been 
reported90. JVM-2 cells have wildtype TP53212 and RB1213 and are assumed to have 
retained the integrity of the G1/S checkpoint. Checkpoint activation after a mitotic 
catastrophe may inhibit new rounds of DNA replication. Endoreduplication have 
previously been shown in staurosporine treated U698 cells, but this treatment 
abolished mitosis and resulted in mononucleated cells214. Hence, another 
mechanism is the cause of PARP inhibitor induced endoreduplication with failed 
cytokinesis after mitosis. The possibility of uncoupling the order of cell cycle phases 
has been seen in normal, although specialized cells, like hepatocytes215 and during 
meiosis. Interestingly, PARPs is known to interact at centrosomes216-218 and 
PARylation of several important spindle assembly checkpoint-proteins such as 
AURKB has been reported76. In addition, PARP inhibitor PJ34 has recently been 
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shown to kill cancer cells with supernumerary centrosomes selectively by 
declustering of the centrosomes during mitosis219. The mitotic aberrations of JVM-2 
and U698 cells might therefore be used as a model system in further studies of the 
role of PARP in the spindle assembly checkpoint. 
The principle of drug-induced synthetic lethality is based the enhancement of the 
effect(s) of one drug by another drug, which itself has no effect. As the ATM inhibitor 
alone had impact on growth rates, drug synergy must in principle be determined by 
using three different concentrations of this drug as well. However, an additive effect 
can be predicted if the dose response curves of the PARP inhibitor are in parallel 
with and without ATM inhibitor (assuming non-mutual interactions of these 
inhibitors). This was the case for Granta-519 (figure 3-5), which may indicate that the 
presence of ATM inhibitor is not related to the DNA repair functions of ATM 
(discussed above). In contrast, the three other cell lines had diverging dose response 
curves, and U698 cells showed the most pronounced deviation from additivity. 
Concerning PARP inhibitor induced cell death (JVM-2 and U698) and apoptosis (Reh), 
there was a clear enhancement of the effect after additionally inhibiting ATM (ATM 
inhibitor had no effect alone). Apoptosis was somewhat higher in Granta-519 cells 
treated with ATM inhibitor alone, but the dose response curves (figure 3-7) were in 
parallel, indicating additive effect of ATM inhibition combined with PARP inhibition 
on apoptosis as well. 
The induced increase in DSBs during S phase (figure 3-11) does not distinguish 
between the “PARP trapping-model”, “replication restart model” 159 or “Balance of 
DSB repair mechanisms” model (figure 1-5). Yet one could speculate that the 
proposed inability to restart stalled replication forks would cause failure to complete 
DNA replication, and possibly death from S phase. This is not in agreement with our 
data, as the cells acquire tetraploid DNA content and G2 delay is more severe than S 
phase delay. Farmer et al. revealed complex rearrangements and chromatid breaks 
by chromosome analysis after PARP inhibition of BRCA1 /2-deficient cells1. Thus, the 
repair of DSBs in these cells has probably not been homology-dependent. The 
mitotic catastrophe phenotype in U698 and JVM-2 indicates failure of the mitotic 
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machinery or chromosome segregation-trouble due to possible complex 
chromosomal rearrangements. This may be due to aberrant repair of multiple DSBs 
by NHEJ, in agreement with the “Balance of DSB repair mechanisms model”.  
From our current data, we cannot establish whether Reh and Granta-519 died from 
G2 or mitosis. DNA fragmentation is a late event in apoptosis and pHistone H3 
(Ser10) positive cells was not observed to be additionally TUNEL-positive. TUNEL may 
not be a valid assay of apoptosis from mitosis at such a late stage in apoptosis. 
Further studies of possible chromosomal rearrangements in all cell lines and 
determination of which cell cycle phase Granta-519 and Reh die from are required. 
This may determine whether PARP and ATM inhibition causes chromosomal 
rearrangements, leading to mitotic catastrophe in U698 and JVM-2. Additionally, the 
duration-dependent increase of PARP inhibitor treatment (figures 3-2, 3-4 and 3-6) 
suggest that damage not associated with γH2AX may accumulate with increasing 
numbers of cell cycles. The possibility of using PARP inhibitors over a long period of 
time further emphasizes the importance of this finding, as the effect would be more 
and more severe throughout the treatment course. 
The underlying background for this study was the attractive possibility of using PARP 
inhibitors in treatment of ATM-deficient cancers. A recent study by Williamson et al.9 
suggested that the ATM inhibitor KU-55933 could be used in combination with PARP 
inhibitor olaparib in treatment of TP53-deficient malignancies. Our data does not 
support this proposition, as ATM and PARP inhibited TP53-proficient cell lines 
(Granta-519, Reh and JVM-2) reveals the substantial amount of damage to the 
normal tissue this would induce (figure 3-2). However, the perspective of additional 
sensitization to PARP inhibitors in tumors with both ATM and TP53 loss, which is 
reported in 10% of all MCLs21, is in agreement with our results. The TP53 negative 
cell line (U698) was the most sensitive to combined PARP and ATM inhibition and 
interestingly the least sensitive to PARP inhibitor alone (figures 3-4, 3-5, 3-15, 3-16 
and 3-19). This is in agreement with the reported lack of PARP inhibitor response in 
TP53 deficient cells9. Although TP53 loss might contribute to PARP inhibitor and HRR-
defective synthetic lethality, it is not by itself a synthetic lethal combination with 
PARP inhibitor.  
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Our results are in agreement with previous studies, stating that the synthetic 
lethality of PARP inhibition and loss of ATM function1,4,7,8,220  is less pronounced than 
the effect of PARP inhibition in BRCA1/2-defective cell in vitro1,2. Since BRCA1 and 2 
are essential for HRR221,222 and ATM is involved in the upstream signalling of HRR77, 
this is not surprising. Yet the possibility of providing patients with ATM-deficient 
malignancies (e.g. aggressive MCL) with a low side effect-treatment option, such as 
PARP inhibitors141,142,  is still attractive. Although the PARP inhibitors did not have 
the desired kill efficiency as a single agent, it is still a possibillity to enhance 
treatment effect of current DSB inducing-chemotherapy and/or irradiation with 
PARP inhibitors. Such studies are presently being performed145,223-225 . 
5 CONCLUSION 
The findings of this study show that PARP and ATM inhibition will generate DSBs 
during DNA replication. The DSBs are subsequently repaired/attempted to be 
repaired during G2, causing a DNA damage-induced G2 delay. Cells without fully 
repaired DNA are not allowed to enter mitosis, and could die by apoptosis directly 
from G2 (Granta-519 and Reh). The cumulative nature of the effect of PARP and ATM 
inhibition suggests that low fidelity DNA repair takes place. The high frequency of 
failed cytokinesis (mitotic catastrophe) is possibly due to difficulty in separating 
structurally abnormal chromosomes (JVM-2 and U698). Cell cycle progression is 
slowed through S and G2 in response to the DNA damage, but the treatment do not 
cause cells to stop cycling. Thus, the continuous exposure to the inhibitors ensures 
that each cycle is likely to cause new DNA damage and erroneous repair. The 
repeated process will inevitably lead to cell death, as the genome becomes 
increasingly damaged (figure 5-1). The cell line specific differences in treatment 
induced phenotypes and cell death mode may be due to other aberrations in the 
DNA damage response system. E.g., the difference between endoreduplication 
(U698) and post-mitotic arrest (JVM-2) could be attributed to the impaired G1/S 
checkpoint in U698 (TP53 loss). 
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Figure 5-1: Proposed cumulative cycle of damage, repair and eventually synthetic lethality 
caused by PARP inhibition while ATM activity is suppressed. 
6 FUTURE PERSPECTIVES 
As this study was time limited, we still have several ideas that we wish to pursue in 
our further study of the phenotypes induced by PARP and ATM inhibition in 
lymphoid cells. 
The apoptotic cells (measured by DNA fragmentation) in this study was mostly 
pHistone H3 negative. This could indicate that apoptosis occurred from G2. However, 
we must first ensure that this phospho-epitope is not lost before the DNA 
fragmentation stage of apoptosis. We plan to induce apoptosis from mitotically 
arrested cells, by long term (24h) nocodazole treatment, as we have previously done 
in U698 and Reh208. Then we will co-stain for both pHistone H3 and DNA-
fragmentation (TUNEL-assay). If these apoptotic cells retain pHistone H3, we will be 
able to conclude that Granta-519 and Reh became apoptotic from G2.  
Secondly, we will perform karyotyping of PARP and ATM inhibited cells. This could 
determine whether the mitotic abnormalities observed in JVM-2 and U698 cells are 
caused by structural chromosome damage such as ring-chromosomes, dicentric 
chromosomes or other complex rearrangements, which is bound to cause failed or 
catastrophic cytokinesis.  
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In this study we have not addressed whether PARP inhibition just causes an increase 
in DNA damage (PARP trapping-model and replication restart model in figure 1-5 B 
and C)159, or if it is the switch to improper and/or inefficient DNA repair that causes 
synthetic lethality in HRR-deficient cells (Balance of repair mechanisms-model in 
figure 1-5 D). To test the latter model, we are going to employ a specific inhibitor 
against DNA-PK (NU-7026). DNA-PK inhibition is reported to rescue cells from 
synthetic lethality of PARP and ATM inhibition9. We wish to further evaluate the 
phenotypes of DNA damage, proliferation and cell cycle specific delay, after this 
proposed rescue. NHEJ is suggested to be 53BP1-dependent171. Thus, we would like 
to stain for 53BP1-associated DSB foci in PARP and ATM inhibited cells, as this might 
reveal whether a shift towards NHEJ is the cause of synthetic lethality. Expression 
profiling by microarray of DNA-PK, PARP and ATM inhibited cells, compared to all 
dual inhibitor combinations and single agents, is also something we plan to perform. 
This might shed more light on the unknown mechanisms of synthetic lethality in DNA 
repair. 
There are conflicting results after PARP knockdown in the literature1,2,12. If the 
correct mechanism of PARP inhibition is the PARP trapping-model, the phenotypes 
induced by PARP knockdown should be less severe than the PARP inhibition induced 
phenotypes. We will also elucidate whether this is the mechanism behind synthetic 
lethality in HRR-defective cells by comparing double knockdown of PARP1 and PARP2 
to PARP inhibition. 
We wish to confirm that TP53 is responsible for the post-mitotic arrest in JVM-2 cells 
by shRNA-mediated knockdown of TP53 in JVM-2, by investigating the possible 
induction of endoreduplication after PARP and ATM inhibition.  
It seems likely that the cells entering G2 phase have γH2AX foci and are positive for 
γH2AX by flow cytometry. After repair of the DSBs, they may enter a γH2AX negative 
compartment in G2 before entry into mitosis (see JVM-2 and Granta-519 in figure S4 
in the appendix). This will be tested by BrdU pulse labeling of cells (followed by pulse 
chasing) for directly determining the order of γH2AX compartments in G2. 
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1 MATERIALS 
Table S1: List of materials used, ordered alphabetically by product. N/A = Not applicable 
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SOLUTIONS 
BD Cell Viability kit: 
The kit was allowed to reach room temperature before use. 
Per ml sample:  
- 1 μl Propidium iodide (4.3 mM) 
- 2 μl Thiazole Orange (42 μM) 
Each sample was added thoroughly mixed 50 μl BD Liquid Counting Beads, using the reverse 
pipetting technique for better accuracy.  
TUNEL-assay:  
The Recombinant Terminal Transferase kit, Biotin-16-dUTPs and DTT solution was allowed to 
reach room temperature before use. 
Table S2:  One sample recipe for a TUNEL reaction, optimized for minimal reagent use. 
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Western Blotting 
2x Loading buffer: 
- 4.0 ml 10% (w/v) SDS      
- 2.0 ml Glycerol 
- 0.1% (w/v) Bromophenol Blue 
- 2.5 ml Tris-HCl (0.5M) pH 6.8  
- 0.5 ml DTT (0.1M) 
- 2 ml ddH2O for a total volume of 10 ml  
10x Blotting salts: 
- 30.0 g Trizma Hydrochloride 
- 144.0 g Glycine 
- Dissolved in ddH2O for a total volume of 1000 ml 
Transfer buffer: 
- 1:10 10x Blotting salts 
- 2:10 Methanol 
- 7:10 ddH2O 
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PRIMARY ANTIBODIES 
Table S3: List of primary antibody specifications, dilution and secondary antibody used for 
immunofluorescence (IF), or Western blotting (WB). Immunoflourescence methods used 
were flow cytometry analysis and sorting and fluorescense microscopy. For IF all 
antibodies were diluted in PBS containing 5%(w/v) dry milk. Antibodies used for WB were 
diluted in TBS-T with 5% dry milk. Primary antibody = 1°Ab, secondary antibody = 2°Ab. 
*For optimalized phospho-ATM signal the amount of antibody-solution used during 
incubation was twice the normal volume. 
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SECONDARY ANTIBODIES 
Table S4: Specifications of the secondary antibodies used in immunofluorescense or 
Western blotting. 
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2 CALCULATIONS 
 
Figure S1: SPSS output after linear regression of dead cells as a function of apoptotic cells. 
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3 SUPPLEMENTARY MATERIAL 
 
144 HOUR TREATMENT OF U698 CELLS 
As there were only a few % diploid G1 cells after 144h treatment with 10µM ATMi and 3 µM 
PARPi, a 50:50 mixture with the 144h control sample was analyzed using flow cytometry 
(figure 2). The persistant 8n and 16n populations prove that the treatment causes 
endoreduplication in U698 cells. 
 
Figure S2: U698 cells after 144h treatment. Mixed sample-control of the mock-treated 
sample and sample treated with 3µM PARPi and 10µM ATMi. 
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MITOTIC AND APOPTOTIC CELLS DURING ENDOREDUPLICATION IN THE U698 
CELL LINE 
 
Figure S3: Fluorescence microscopy images of U698 cells after 144h treatment with PARPi 
(olaparib) and 10µM ATMi (KU-55933). 
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γH2AX INTENSITY DURING G1, S AND G2  
 
Figure S4: Flow cytometry analysis of γH2AX intensity relative to DNA content (doublets, 
mitotic and apoptotic cells are excluded) after 48h treatment with PARP inhibitor 
(olaparib). Dot plots and corresponding contour plots are shown for all cell lines. 
